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CHAPTER I 
 
INTRODUCTION 
 
      TGF-β signaling 
 
TGF-β signaling pathway 
 
TGF-β ligands and ligand binding proteins 
  The Transforming Growth Factors-beta (TGF-β) superfamily of cytokines are 
multifunctional molecules that play pivotal roles in the control of cell proliferation, 
differentiation, cell adhesion, cell motility, apoptosis, extracellular matrix production, skeletal 
development, haematopoiesis, inflammatory responses, and wound healing (reviewed in [1, 2]).  
This superfamily is composed of two subfamilies of cytokines; the TGF-β/Activin/Nodal 
subfamily and the Bone Morphogenic Protein (BMP)/Growth and Differentiation Factor 
(GDF)/Muellerian Inhibiting Substance (MIS) subfamily [2] (Fig. 1).  There are three 
mammalian TGF-β isoforms, TGF-β1, TGF-β2, and TGF-β3, which are encoded by distinct 
genes on different chromosomes and are expressed in both a tissue-specific and in a 
developmentally regulated fashion [3].  Of these isoforms, TGF-β1 (TGF-β) is most frequently 
up-regulated in human neoplasia [4, 5] and is the focus of studies in our laboratory.   
  TGF-βs are synthesized as pro-cytokines that are cleaved into corresponding amino-
terminal pro-peptides, LAPs (latency-associated proteins) and carboxy-terminal fragments (the 
mature cytokines) [6].  Unlike most other cytokines, mature TGF-βs remain non-covalently 
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associated with LAPs in forms that are not recognized by its signaling receptors.  The 
physiological activation process of latent TGF-βs is probably a multi-step process involving 
proteolysis by protease systems such as the urokinase plasminogen activator (uPA) system [7, 8].  
The activation of TGF-β by uPA has been demonstrated in several tissues and cell types 
especially in pathogenic contexts [7, 8].   
  Ligand access and activity of the signaling receptors is also regulated by various families 
of diffusible proteins known as ligand binding traps [9] including Noggin, Chordin, and 
Follistatin (Fig. 1).  Follistatin is a soluble secreted glycoprotein that suppresses Activin activity 
through inhibition of Activin binding to its receptors [10].  Although originally identified as an 
Activin-binding protein, Follistatin was shown to inhibit all aspects of bone morphogenetic 
protein (BMP) activity in early Xenopus embryos [11].  Interestingly, Follistatin was found to 
noncompetitively inhibit the BMP receptor function by forming a trimeric complex with BMP 
and its receptor [11].  Unlike Follistatin, Noggin [12] and Chordin [13] function as BMP 
antagonists by interfering with BMP binding to its cell-surface receptor.  
 
TGF-β signal transduction 
  TGF-β ligands signal through various type I and II transmembrane serine/threonine 
kinase receptors (Fig. 1).  A type II receptor is necessary for specific ligand binding [2, 14].  
Once bound to ligands, type II receptors recruit, bind, and transphosphorylate type I receptors, 
thereby stimulating type I receptor protein kinase activity.  Following ligand binding and 
receptor activation, information from the tissue microenvironment to the cell nucleus by these 
growth factors is then transmitted by specific receptor-associated Smad (R-Smad).    Eight 
members of the vertebrate Smad family of protein have been identified and are referred to as 
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Figure 1. Schematic relationship describing TGF-β ligands, 
ligand binding traps, accessory receptors, and the type I and 
type II receptors. Downstream R-Smads 1, 2, 3, 5 and 8 are 
grouped based on their signaling specificity.  Smad2 and 3 mediate 
TGF-β and activin signaling whereas Smad1, 5, and 8 transduce BMP 
signaling.  Figure from Shi Y. and Massague J., Cell. 2003. 113:685-
700.
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Figure 2. Schematic diagram of TGF-β signaling from cell 
membrane to the nucleus. TGF-β family ligands bind to type II 
receptors which then recruit and activate type I receptors by 
phosphorylation. Subsequently, R-Smads activated and 
phosphorylated by type I receptors complex with the Co-Smad 
(Smad4) and then translocate into the nucleus, where they regulate 
the expression of TGF-β target genes in a cell-type specific manner. 
The arrows indicate signal flow and are color coded: orange for ligand 
and receptor activation, gray for Smad and receptor inactivation, 
green for Smad activation and formation of a transcriptional complex, 
and blue for Smad nucleo-cytoplasmic shuttling. Phosphate groups 
and ubiquitin are represented by green and red circles, respectively.  
Figure from Shi Y. and Massague J., Cell. 2003. 113:685-700.
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Smad1 through Smad8 [2] (Fig. 1).  As a general rule, Smads1, 5, and 8 transduce signals from 
the bone morphogenetic proteins (BMPs) through BMP-specific receptors whereas Smads2 and 
3 transduce signals downstream of TGF-β and Activin signals [2, 15].  After phosphorylation by 
a type I receptor, R-Smads associate with the common-Smad (Co-Smad), Smad4, and translocate 
to the nucleus to regulate transcription of a multitude of TGF-β target genes, independently or in 
association with DNA-binding partners (Fig. 2).  Smad6 and Smad7 are inhibitory Smads (I-
Smads) that counteract Smad-mediated signaling by interfering with type I receptor-mediated R-
Smad phosphorylation [2]; in general, Smad6 preferentially inhibits BMP signaling whereas 
Smad7 can inhibit both TGF-β and BMP signaling.   
Although Smad2, Smad3, and Smad4 comprise the core Smad-dependent TGF-β 
signaling pathway, accumulating evidence suggests that Smad-independent TGF-β signaling may 
also occur in cells. Smad-independent TGF-β signaling may be mediated through the mitogen-
activated protein kinase (MAPK), Rho guanosine triphosphatases, PI-3 kinase/Akt, and protein 
phosphatase 2A signaling pathways (reviewed in [16]).  However, activation of these pathways 
appears to be cell context-dependent.  For example, TGF-β activation of the Ras/Raf/MAPK 
pathway required expression of oncogenic Ras in selected cells [17].   
  
TGF-β in cancer 
  TGF-β has been considered both a tumor suppressor and tumor promoter.  Generally, 
TGF-β may elicit anti-tumorigenic effects at early stages during carcinoma development, while 
exhibiting tumor promoting effects in later stage cancer (Fig. 3).   
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Tumor suppression by TGF-β 
  Most pertinent to our understanding of the role of TGF-β in carcinoma development is 
the fact that TGF-β is a potent inducer of growth inhibition [18-20] and apoptosis [21] in several 
cell types, primarily epithelial lineages.  Virtually almost all epithelial-derived tumors (>85% of 
all human cancers) lose the growth-inhibitory response to TGF-β [22].  In some cancers, 
including colon and pancreatic cancers, mechanisms for resistance such as functional 
inactivation of the Smad proteins (predominately Smad4) or the TGF-β receptors (predominately 
TβRII) [22] are well defined.  However, in other cancers such as breast, lung, and prostate, the 
mechanisms for resistance to TGF-β’s growth inhibitory effect remain poorly understood.  
Therefore, abrogation of TGF-β signaling leading to a loss of growth inhibition is considered one 
of the mechanisms for the loss of protection against tumor progression.  The role of TGF-β as a 
tumor suppressor is further highlighted by the in vivo studies involving genetic manipulations of 
expression of components of TGF-β signaling pathway in tumor cells [23] [24].  For example, 
overexpression of a TGF-β type II receptor reduced the tumorigenicity and metastatic potential 
of K-ras-transformed thyroid cells [23], whereas expression of dominant-negative forms of 
TβRII in mammary gland increased tumor formation induced by a chemical carcinogen in mice 
[24].   
  One key event that leads to TGF-β-induced growth arrest is the induction of the CDK 
inhibitors, p15INK4B [25] and p21CIP1 [26].  p21CIP1 interacts with complexes of CDK2 and 
cyclin A or cyclin E thereby inhibiting CDK2 activity and preventing progression of the cell 
cycle [27].  By contrast, p15INK4B interacts with and inactivates CDK4 and CDK6 or associates 
with cyclin D complexes of CDK4 or CDK6.  The latter interaction not only inactivates the 
catalytic activity of these CDKs but also displaces p21CIP1 or the related p27KIP1 from these 
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complexes, allowing them to bind to and inactivate the CDK2 complexes with cyclin A and E 
[27, 28].  Additional mechanisms underlying TGF-β-mediated growth arrest include indirect 
suppression of c-Myc [29] and CDK4 [30] protein expression.  
  Programmed cell death or apoptosis is a key cellular response that controls cell numbers. 
TGF-β has been shown to induce apoptosis in several cell types [21, 31] and in a number of 
cancers such as breast, gastric, hepatic and prostate cancers [31].  TGF-β-induced apoptosis has 
been shown to be mediated by the Smad-dependent pathway [32, 33].  However, the inhibitory 
Smad, Smad7, promotes TGF-β–induced apoptosis in prostate carcinoma cells [34].  There are 
also studies showing involvement of Smad-independent pathways in this TGF-β action [35].  For 
example, Daxx adaptor protein, a protein associated with the Fas receptor that mediates 
activation of Jun amino-terminal kinase (JNK) and programmed cell death induced by Fas, has 
been proposed to mediate TGF-β–induced apoptosis through interaction with a TGF-β type II 
receptor [35].  The downstream events that lead to apoptosis induced by TGF-β include down-
regulation of anti-apoptotic factors such as Bcl-XL [36] and up-regulation of pro-apoptotic 
factors such as caspases 3 and 8 [37]. 
 
TGF-β enhances tumor progression 
  Solid tumors exhibit lethal effects by invading into surrounding tissues and metastasizing 
to distant sites in the body.  Clinically, elevated TGF-β has been detected in late stage cancer and 
is frequently associated with advanced disease [31].  TGF-β displays the capacity to promote 
tumor progression in cancers through various mechanisms [38-42].  Among these functions, 
TGF-β has an important role in the regulation of metastasis and epithelial-to-mesenchymal 
transition (EMT) in cancers [43-45].  Epithelial-to-mesenchymal transition (EMT) has been 
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Figure 3. Activation of and dual roles for tumor and 
stromal TGF-β in tumorigenesis through interaction 
with the tumor cell and its environment. Both tumor 
and stromal cells secrete elevated levels of TGF-β that 
are self-perpetuating via a cycle of enhanced protease 
activation of latent TGF-β, auto-induction of TGF-β gene 
activity. Most TGF-β activities, apart from the growth 
inhibition of early tumor cells, promote tumor progression. 
ECM, extracellular matrix; Fas-L, Fas ligand.  Figure from 
Derynck, Rik, et al., Nat. Genet. 2001. 29:117-129. 
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shown to  correlate with increased invasive and metastatic capacity of tumor cells (reviewed in 
[46]) during cancer progression.  TGF-β was described as an inducer of EMT first in normal 
mammary epithelial cells [41] and later in tumors.  This TGF-β’s function was demonstrated in a 
study showing that ectopic TGF-β expression keratinocytes in transgenic mouse appeared to 
enhance progression of the cells toward a more malignant spindle-cell phenotype in advanced 
lesions after long-term treatments of a chemical carcinogen [47].  Moreover, TGF-β also 
promotes the EMT that accompanies invasive and metastatic growth of transformed cells [48, 
49].  In a highly metastatic mesenchymal mouse colon carcinoma line (CT26), overexpression of 
a dominant-negative TGF-β type II receptor (DN-TβRII) blocked TGF-β signaling and induced 
reversal of EMT in these cells.  Expression of the DN-TβRII also inhibited cell invasion and 
abolished metastasis formation by CT26 cells.  In addition, after undergoing EMT, tumor cells 
may acquire altered TGF-β responsiveness such as resistance to the tumor-suppressor effects of 
TGF-β [50].  Thus although TGF-β can inhibit tumor growth, there is increasing evidence that 
TGF-β secretion by tumor cells and/or stromal cells within the peri-tumoral microenvironment 
contributes to tumor maintenance and progression [43, 51, 52].   
  TGF-β exhibits activity that directly contributes to metastatic growth [53] [54].  In the 
metastatic 4T1 breast cancer cells expression of a dominant-negative truncated type II receptor 
diminished TGF-β signaling and significantly restricted the ability of 4T1 cells to establish 
distant metastases [53].  The same group also showed that a soluble Fc:TGF-β type II receptor 
fusion protein (Fc:TβRII) inhibited breast cancer metastases in transgenic and xenograft mouse 
models. Similarly, Yang et al [54], developed transgenic mice expressing a TGF-β antagonist of 
the soluble Fc:TβRII fusion protein class, under the regulation of the mammary-selective 
MMTV-LTR promoter/enhancer. These mice were resistant to the development of metastases at 
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multiple organ sites when compared with wild-type controls, both in a tail vein metastasis assay 
using isogenic melanoma cells and in crosses with the MMTV-neu transgenic mouse model of 
metastatic breast cancer.   
  Cancer cells can proliferate independently of exogenous mitogenic growth signals 
through either overexpression of the mitogenic growth factors or constitutive activation of 
mitogenic signaling pathways.  TGF-β can stimulate the proliferation of a number of epithelial-
derived cancer cell lines, including colon, pancreatic, and prostate cancer cells by, in part, 
increasing the expression of mitogenic growth factors or their receptors (reviewed in [22]).  In 
addition, TGF-β can activate the proliferative Ras/Raf/MAPK pathway in a Smad-independent 
manner in cells that express oncogenic Ras protein [55]. 
  TGF-β is one of the several cytokines that coordinate to regulate angiogenesis, which is 
frequently associated with deregulated expression of vascular endothelial growth factor (VEGF).  
The presence of TGF-β in the microenvironment of tumor sites thus might indirectly provide 
solid tumors with nutrients and oxygen supplies though modulating angiogenesis.  TGF-β has 
been shown to potentiate the hypoxic response in human HT-1080 fibrosarcomas [56] and 
increases VEGF transcription by enhancing the DNA-binding activity of the transcriptional 
factors, AP-l and HIF-1, and may.  Moreover, TGF-β-enhanced liver metastatic potential of 
human pancreatic cancer cell lines, Capan-2 and SW1990 was associated with VEGF production 
[57].  
Although there are multiple mechanisms by which cancer cells evade immune  responses, 
a major mechanism is escaping from cancer cell-mediated immune response via secretion of 
TGF-β [58].  This immuno-suppressive activity of TGF-β is suggested by the following 
observations showing that a highly immunogenic tumor transfected with a murine TGF-β cDNA 
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escaped immune surveillance and formed tumors in animals [59] and anti-cancer cell immune 
responses can be augmented by blocking the TGF-β signaling pathway in T cells [60]. 
  
Autocrine and paracrine TGF-β  
  Cancer cells express receptors enabling them to respond to a variety factors derived from 
the non-tumor cells in tumor and stromal microenvironments [61].  Additionally, cancer cells can 
synthesize and secrete various growth factors that contribute to malignant tumor growth through 
autocrine mechanisms [40] (Fig. 2).  The impact of tumor-derived TGF-β on cell invasion and 
metastasis through autonomous mechanisms has been documented [40, 49].  For example, 
disruption of autocrine TGF-β signaling by a dominant-negative type II receptor (DNIIR) 
inhibited the invasive and metastatic potential of mammary and colon carcinoma cells [49].  This 
effect was attributed to the prevention of autocrine TGF-β-induced epithelial-to-mesenchymal 
transition (EMT), a process believed to promote tumor cell migration and invasion [62].  
Furthermore, inhibition of autocrine TGF-β signaling by over-expression of a soluble TGF-β 
type III receptor, which antagonizes TGF-β activity caused inhibition of proliferation and 
induction of apoptosis [40].  These data demonstrate a role for autocrine TGF-β in regulation of 
cancer cell behavior.  The mechanism by which autocrine TGF-β may selectively contribute to 
tumor cell behavior was explored in the first part of my study using the breast cancer cell line 
MDA-MB-231 [63].  MDA-MB-231 cells express MMP-9 and uPA [51].  Elevated MMP-9 and 
uPA activity has been linked to metastatic growth of cancer cells and poor patient outcome [64-
66].  We hypothesized that autocrine TGF-β could function as a tumor promoter through 
regulation of MMP-9 or uPA activity in these cells. 
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Development of TGF-β signaling inhibitors for cancer therapy 
Deregulation of TGF-β has been implicated in the pathogenesis of a variety of diseases, 
including cancer and fibrosis disorders [22, 67].  The role of TGF-β in cancer biology is complex 
and involves aspects of tumor suppression as well as tumor promotion. The ability of TGF-β to 
potently inhibit the proliferation of epithelial, endothelial and haematopoietic cell lineages is 
central to its tumor-suppressive function [68].  However, as tumors progress, they often become 
refractory to TGF-β-mediated growth inhibition and even overexpress TGF-β, which in turn has 
a marked impact on the biology of the tumor cells themselves and creates a tumor micro-
environment that is conducive to tumor growth and metastasis.  Therefore, antagonism of TGF-β 
signaling will potentially have an impact on physiological and pathological activity of TGF-β in 
normal and tumor cells.   
 
Large-molecule TGF-β signaling inhibitors 
The more advanced TGF-β signaling antagonists in clinical development are large 
molecules, including monoclonal antibodies [69, 70] and antisense oligonucleotides [71] that 
target the TGF-β protein molecule and the TGF-β mRNA, respectively.  Initial efforts to develop 
the large-molecule TGF-β signaling antagonist approaches because selective inhibition of the 
receptor kinase in the heteromeric receptor and Smad signaling complex was not thought to be 
achievable.  Therefore, the large-molecule antagonists of TGF-β signaling are more advanced 
than the small-molecule antagonists.  Nevertheless, delivery issues for the large-molecule TGF-β 
antagonists [72], might limit their application to particular disease states. The ability of TGF-β to 
signal in an autocrine mode could also limit the effectiveness of antibody therapies in solid 
tumours. 
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Small-molecule TGF-β receptor kinase inhibitors 
The extensive knowledge surrounding TGF-β receptor kinase-dependent Smad2/Smad3 
phosphorylation as an early event of TGF-β signal transduction has focused the development of 
Small-molecule TGF-β receptor kinase inhibitors as a therapeutic target [73, 74].  These 
inhibitors have key functional centers that potently bind to the kinase-domain active sites of the 
TGF-β receptors and thus act as ATP-competitive compounds [74].  Although the development 
of small-molecule kinase inhibitors may overcome the delivery and tissue-penetration issues, 
these inhibitors are inherently less selective than antisense or antibody therapies.  In addition, it 
is anticipated that the pharmacokinetic properties of antibody and small molecule kinase 
inhibitors will result in considerable differences in the duration of TGF-β signaling modulation.  
In general, antibody therapy will have a prolonged duration of activity relative to the small-
molecule kinase inhibitors.  Thus, the differences in mechanisms of action and pharmacokinetic 
properties make future combination therapies of small-molecule TGF-β receptor kinase 
inhibitors and neutralizing antibody therapies very attractive.   
Although previous studies and our work have shown the therapeutic potential of 
inhibiting TGF-β signaling and the efficacy of the TGF-β receptor kinase inhibitor in suppressing 
tumor cell invasion, respectively, there are many reports that have highlighted the importance of 
the tumor-suppressive role of TGF-β, and how the absence of TGF-β signaling can exacerbate 
tumorigenesis [24, 75].  This underscores the need to carefully define patient populations in 
which the tumor promoting role of TGF-β signaling predominates.  Moreover, it will be valuable 
for investigating the molecular nature and stage of tumors that are susceptible to TGF-β 
antagonism, and, conversely, for identifying the stages at which the tumor-suppressive role of 
TGF-β signaling remains operative. 
 14
Smad functions 
 
Smad transcriptional regulation of gene expression 
  Smad proteins consist of three domains, namely the highly conserved amino-terminal 
(MH1) and carboxy-terminal (MH2) domains, and the intervening linker region with variable 
length and sequence [2].  The MH2 domain displays transcriptional activity in a heterologous 
fusion with a GAL4 DNA binding domain in transcriptional studies.  Smads (most R-Smads) and 
the Co-Smad (Smad4) bind to DNA in a sequence-specific manner.  The minimal Smad binding 
element (SBE), was initially identified as the optimal DNA binding sequence 5’-AGAC-3’ [76]; 
however most naturally occurring DNA sequences contains an extra base “C” at the 5’ end.  In 
addition to the SBE, certain G/C-rich sequences have been reported to be Smad1, Smad3, and 
Smad4 binding elements [77, 78].   
  TGF-β stimulation leads to positive and negative regulation of several hundred target 
genes.  Both activation and repression of gene expression use the same set of activated Smad 
proteins, suggesting that Smads must cooperate with each other and/or with other DNA binding 
partners to elicit specific transcriptional responses.  A general hypothesis for how cells respond 
to TGF-β signals posits that Smad access to target genes and the recruitment of transcriptional 
coactivators or corepressors to such genes depends on the availability of specific partner proteins 
in different cell context and conditions that affect the cell at the time of TGF-β stimulation.   
Indeed, the MH2 domain of both R-Smads and Smad4 has been shown to interact with the 
transcriptional coactivators CBP/p300 [79] and Smif [80] as well as the co-repressors Ski and 
SnoN.  Ski and SnoN are two highly conserved members of the Ski family of proto-oncoproteins 
[81].  Ski and SnoN antagonize TGF-β signaling through direct interactions with Smad4 or the 
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R-Smads.  The mechanisms of Ski-mediated repression of TGF-β signaling are primarily 
attributed to transcriptional modulation through recruitment of the nuclear transcriptional 
corepressor (N-CoR) and histone deacetylase (HDAC) and interference of Smad-mediated 
binding to the transcriptional coactivator, p300/CBP [81].  Thus, by functioning in conjunction 
with various positive and negative (co)activators or (co)suppressors, Smad proteins can mediate 
transcriptional activation or repression depending on their associated partners. 
 
The roles of Smad in cancer 
  Smads are important intracellular effectors in mediating TGF-β-induced growth 
inhibition and apoptosis [32, 33].  Loss of the normal growth inhibitory response to TGF-β has 
been linked to functional inactivation of type II TGF-β receptors (TβRII) or Smad proteins.  The 
most commonly lost Smad mediator in cancers is Smad4.  Functional inactivation of Smad4 was 
detected in pancreatic (~50%) [82] and colorectal (20-30%) [83, 84] cancer and in 80% of 
adenocarcinomas of the small bowel [84].  Furthermore, loss of Smad 4 expression is correlated 
with liver metastasis and poor prognoses in colon cancer patients [83, 84].  Smad4 displays 
tumor suppressive functions primarily through mediating TGF-β-induced growth inhibition and 
apoptosis.  Recent evidence suggests that Smad4 has additional tumor suppressive functions [85-
87].  For example, expression of Smad4 in Smad4- and E-cadherin-deficient colon carcinoma 
cells resulted in reversal of epithelial-to-mesenchymal transition (EMT), increased E-cadherin 
expression, and the loss of tumorigenesis of the cells in nude mice [85-87].  In addition, these 
phenotypic changes were associated with reduced protein expression of prognostic markers such 
as urokinase plasminogen activator (uPA) and plasminogen-activator-inhibitor-1 (PAI-1) [38, 66, 
87].  In a separate study, restoration of Smad4 in pancreatic carcinoma cells suppressed tumor 
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formation in vivo [88].  Further, the Smad4-expressing cells produced less angiogenic factor, 
vascular endothelial growth factor (VEGF), and developed to smaller non-progressive tumors 
with reduced vascular density when compared with Smad4-deficient parental cells.  Collectively, 
these data define novel mechanisms of tumor suppression by Smad4.  
  Paradoxically, the prevailing evidence suggests that induction of EMT by TGF-β is 
mediated through the canonical Smad2/3 and Smad4 transduction pathway.  In a study led by 
Valcourt et. al [89], either dominant-negative Smad3 or dominant-negative Smad2 could inhibit 
the EMT response of NMuMG mouse mammary epithelial cells to TGF-β. Expression of a 
dominant-negative (C-terminally deleted) Smad4 also inhibited EMT [89].  Thus, Smads-elicited 
tumor suppressive and promoting effects may be dependent on cell context. 
 
Potential for TGF-β signaling-independent roles for Smad4 
 As described above, expression of Smad4 in Smad4-deficient colon carcinoma SW480 
cells reduced the tumorigenicity of the cells [85].  Interestingly, Smad4 expression did not 
restore in vitro growth inhibitory response to TGF-β in the cells, which was probably attributed 
to low levels of type II TGF-β receptor resulting in deficient TGF-β signaling [85].  These data 
suggest that Smad4 may elicit tumor suppressive responses independently of TGF-β signaling.   
 
Urokinase plasminogen activator (uPA) – an important microenvironmental component of 
Cancer 
 
 
The biological functions of the uPA system 
  The urokinase plasminogen activator (uPA) system is central to a spectrum of biologic 
processes including fibrinolysis, inflammation, atherosclerotic plaque formation, matrix 
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remodeling, and growth factor activation [7, 90, 91].  The primary function of uPA is converting 
the inactive pro-enzyme plasminogen into plasmin (Fig. 4).  Plasmin is a serine protease capable 
of degrading components of the basement membrane and extracellular matrix (ECM).  Plasmin 
also triggers activation of ECM-degrading proteases such as metalloproteinases [64] (Fig. 4) that 
have been shown to be linked to the metastatic growth of cancer [38].  Urokinase plasminogen 
activator and plasmin are also involved in the activation or liberation of latent growth factors 
such as vascular endothelial growth factor (VEGF) [92] and TGF-β [93, 94] that play an 
important role during tumorigenesis.  
  Through binding to it receptor, uPA can activate intracellular signaling pathways such as 
the extracellular-signal-regulated kinase-1 and -2 (ERK1/2), p38, and focal adhesion kinase 
(FAK) pathways that are important for proliferation and migration [95, 96] and increase the 
activity or expression of some transcription factors such as AP-1, c-Jun, and c-Myc in certain 
cellular contexts [95].  UPAR-mediated uPA effects can be independent of uPA proteolytic 
activity.  Both pro-uPA and uPA bind with high affinity to uPAR.  Moreover uPA, pro-uPA, and 
protease activity-defective uPA have been shown to be capable of inducing cell migration 
comparatively in selected cells [97, 98]. 
  Besides transducing signals from uPA, uPAR can regulate migration, cell attachment and 
signaling transduction through interaction with vitronectin and integrin [91, 96, 99].   Since 
uPAR lacks transmembrane and cytoplasmic domains and is anchored in the plasma membrane 
by a glycosyl phosphatidyiinosital (GPI) moiety, other membrane partners are probably required 
to transduce uPAR-mediated signal transduction across the plasma membrane.   
protease activity-defective uPA have been shown to be capable of inducing cell migration 
comparatively in selected cells [97, 98]. 
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Figure 4. Diagram of uPA actions. At the leading edge of migrating 
cells, the urokinase receptor (uPAR) binds inactive urokinase (pro-
uPA), which is then converted to active uPA. Active uPA proteolytically
converts the inactive zymogen plasminogen to active plasmin, which 
then breaks down ECM components or activates latent growth factors 
such as transforming growth factor-β1 (TGF-β1). Plasmin can also 
degrade the ECM indirectly through activation of pro-matrix 
metalloproteinases (MMPs).  Figure from Duffy M. J., et al., 2004. Clin. 
Biochem. 37:541-548.
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  Besides transducing signals from uPA, uPAR can regulate migration, cell attachment and 
signaling transduction through interaction with vitronectin and integrin [91, 96, 99].   Since 
uPAR lacks transmembrane and cytoplasmic domains and is anchored in the plasma membrane 
by a glycosyl phosphatidyiinosital (GPI) moiety, other membrane partners are probably required 
to transduce uPAR-mediated signal transduction across the plasma membrane.   
 
The key components of the uPA system 
 
Urokinase Plasminogen activator (uPA) 
  Urokinase plasminogen activator was first identified in urine and later found to be 
expressed in vascular endothelial, smooth muscle, fibroblast, monocyte/macrophage, and 
epithelial cells as well as in tumors of different origins [91].  This protein is secreted by cells as a 
single-chain zymogen (pro-uPA) with a molecular weight of 54 kD and has three functional 
domains: the N-terminal “growth factor-like” domain responsible for receptor binding, the 
central kringle domain that interacts with the uPA inhibitors, plasminogen activator inhibitor-1 
and -2  (PAI-1 and PAI-2), and the C-terminal catalytic domain with serine protease activity with 
a specific amino acid triad, His204, Asp255, and Ser356 in the active center [91] (Fig. 5).  
Activation of pro-uPA involves cleavage of peptide bond between Lys158 and Ile159 by 
proteases including plasmin, elastase, and cathepsin B [91, 99], resulting in the formation of a 
two-chain uPA molecule linked by a disulfide bond.  A low-molecular-weight uPA has been 
detected in human urine [100] and plasma from patients with acute pancreatitis [101].  The low-
molecular-weight form can be generated after further cleavage of the Lys135-Lys136 bond by 
plasmin in the region between the kringle and protease domains (Fig. 3), and its proteolytic 
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Figure 5. Fragments of urokinase plasminogen activator 
generated after proteolytic processing. Activation of pro-uPA 
involves cleavage of the peptide bond between Lys158-Ile159 by 
proteases such as plasmin, elastase, and cathepsin B, resulting in 
the formation of a two-chain uPA molecule linked by a disulfide bond. 
The low-molecular-weight form can be generated after further 
cleavage of the Lys135-Lys136 bond by plasmin in the region 
between the kringle and protease domains.  G: growth factor-like 
domain; K: kringle domain; P: protease domain; MW: molecular 
weight, LMW: low molecular weight. 
MW        Relative 
activity
Single-chain pro-uPA              54 kDa 1
Two-chain active uPA             54 kDa >200
Two-chain inactive uPA          54 kDa 0
Two-chain active uPA             50 kDa >200
Two-chain active uPA
(Most abundant LMW uPA)    32 kDa >200
G P      K
G P      K
S - S
Lys158    Ile159
G P      K
S - S
Arg156    Phe159
P      K
S - S
Ser47
P      
S - S
A chain B chain
His204   Asp255    Ser356
Lys136
Lys158    Ile159
Lys158    Ile159
Lys136
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activity is comparable to the activity of  the full-length two-chain uPA [100, 102].  Although the 
single-chain pro-uPA is a zymogen (pro-uPA), it has some intrinsic activity [103] and thus is 
able to convert its substrate, plasminogen, to plasmin.  Therefore, pro-uPA-mediated generation 
of plasmin will facilitate activation of itself, resulting in cyclic activation of this system.    
 
Urokinase plasminogen activator receptor (uPAR) 
  The 55-60 kD uPAR protein was first identified as a uPA-binding receptor and was later 
found to be an adhesion receptor for vitronectin, a component of ECM [104] as well.  Coincident 
binding of uPA to uPAR and plasminogen to plasminogen receptors on the cell surface strongly 
increases local concentrations of uPA and plasminogen, thereby accelerating conversion of 
plasminogen to plasmin by uPA.  Both pro-uPA and uPA bind to uPAR with high affinity [97, 
98].  While pro-uPA has low intrinsic activity for conversion of plasminogen to plasmin, uPAR 
plays an important role in facilitating the activation of pro-uPA by plasmin and activation of 
plasminogen by uPA.   
 
Plasminogen activator inhibitors (PAI-1 and PAI-2) 
  Plasminogen activator inhibitor-1 and -2 (PAI-1 and PAI-2) are the principle inhibitors of 
uPA activity.  Both PAI-1 and PAI-2 inhibit uPA by forming a complex with active uPA at a 1:1 
ratio [105].  PAI-1 predominates as an inhibitor of uPA, as it reacts with uPA faster than PAI-2 
[105].  After binding, uPA/PAI complexes are internalized by cells in a process requiring binding 
of uPA/PAI to uPAR [106].  The process of internalization leads to the degradation of both uPA 
and PAI-1 while uPAR is recycled to the cell surface [107].  As acceleration of uPA-mediated 
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cell surface activation of plasminogen depends upon uPA binding to uPAR, the clearance of 
inactive uPA/PAI-1 complexes and recycling of uPAR, maintains the cells’ capacity to bind uPA.   
   
Evidence for a role of the uPA system in cancer progression 
  High expression levels of components of the uPA system, including uPA and its cell 
surface receptor (uPAR), have been correlated with poor prognosis in cancers [66, 108].  
Overexpression of uPA is observed in carcinomas and metastases of breast, colon, lung, brain, 
kidney, bladder, liver, and brain cancers [66, 109, 110].  In breast cancer, high levels of uPA in 
tumor tissues predict poor prognosis and shorter survival [66, 109].  Its role in promoting tumor 
invasion and metastasis has also been well documented in a number of in vitro and in vivo 
studies.  In cell cultures, uPA overexpression induced by cytokines promoted cell invasion [38, 
111].  Ectopic overexpression of uPA in murine melanoma B16-F1 cells significantly increased 
metastasize potential of the cells [112].  In the same study, the uPA-overexpressing melanoma 
cells also exhibited a greater capacity to extravasate from the blood vessels and developed into 
pulmonary tumors when compared with control cells.  Conversely, introduction of antisense uPA 
reversed the enhanced metastatic and extravasation potential of uPA-overexpressing melanoma 
cells.   Several other studies also showed that inhibition of expression or activity of the 
components of the uPA system (e.g. using anti-uPA antibodies [113] or synthetic inhibitors of 
uPA [110, 114, 115]) or disruption the interaction between uPA and uPAR [116, 117] leads to a 
reduction in the invasive and metastatic capacity of many tumors.  These data demonstrate a 
critical role for uPA in the development of invasive and metastatic growth of tumors.  
Paradoxically, high levels of the uPA inhibitor, PAI-1, predict shorter patient survival [66, 108].  
These observations indicate a more complex role for PAI-1 in tumor progression and 
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angiogenesis than simple inhibition of uPA. The precise roles for PAI-1 in cancer remain to be 
explored. 
 
Claudin-1 – a tight junction protein and a potential metastatic transformation 
            modulator in colorectal cancer cells   
 
Claudins in cancer 
  Claudin family proteins are integral membrane components of tight junctions with 
molecular weights of ~17–27 kD.   At least 20 claudin family members have been cloned and 
characterized from mouse, rat and human (reviewed in [118]).  Tissue-specific expression of 
claudin proteins allows them to perform specialized cellular functions including maintenance of 
cell polarity and para-cellular barriers in conjunction with other integral membrane partners, 
such as occludin and the junctional adhesion molecule-1 (JAM1) (Fig. 6).  The preservation of 
cell polarity by claudins suggests tumor suppressive functions of claudins in epithelial-derived 
neoplasias.  Actually, loss of claudin expression is associated with tumor progression in cancers 
[119-121].  Paradoxically, overexpression of claudins was also observed in carcinomas and 
metastases in particular cancer types [122-125].  For example, claudin-4 appears to be over-
expressed in ovarian [122] and pancreatic [123] cancer.  In some cases, altered subcellular 
location of claudins was also observed in cancer, including mislocalization of claudin-3 and 
claudin-4 from the membrane to the cytoplasm in ovarian cancer [122] and of claudin-1 in colon 
cancer [125].  Thus, deregulated expression and mislocalization of claudin appears to be 
associated with tumor progression in some cancers; however, its exact roles in cancer 
development remain unclear.   
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Figure 6. Schematic illustration of intercellular 
junctions between epithelial cells. The tight 
junction is located apically on the lateral membrane. 
The claudins comprise one of the integral membrane 
components of the tight junction, where they interact 
with proteins of the ZO family. This interaction in turn 
links the tight junction to the actin cytoskeleton.  
Figure from Folpe A. L., et al., Am J Surg Patho,. 
2002. 26(12): 1620–1626.
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  In human colon cancer, claudin-1 expression is increased in carcinomas and metastases 
[124, 125].  Moreover, genetic manipulation of claudin-1 expression in isogenic variants of 
primary and metastatic colon cancer cell lines, SW480 and SW620, respectively, implicates a 
role for claudin-1 in regulating the metastatic potential of these cells [125].  Over-expression of 
claudin-1 in SW480 cells (non-metastatic) results in hepatic metastases when cells were injected 
into the spleen of athymic mice, while siRNA mediated knockdown of abundant claudin-1 levels 
in SW620 cells (metastatic) results in decreased hepatic metastases [125].  The metastatic 
potential and claudin-1 expression of these cells also correlated with in vitro cell invasiveness 
and anchorage-independent growth.  These data suggest a role for claudin-1 in the regulation of 
invasive and metastatic transformation in colon cancer cells. 
 
Regulation of claudin-1 expression  
 
Snail and Slug regulation of claudin-1 transcription 
  The Snail family of transcriptional repressors (including Snail and Slug) have been 
shown to induce epithelial-to-mesenchymal transition (EMT) through downregulation of the 
adherent junction protein E-cadherin [126].  In promoter studies, Snail and Slug-mediated 
suppression of E-cadherin transcription was shown to require the E-box cis-element in the 
proximal area of the E-cadherin promoter [126, 127].  Recently, Snail and Slug have been 
reported to suppress claudin-1 transcription in Madin-Darby canine kidney (MDCK) cells [128] 
through similar E-box elements in the claudin-1 promoter.  In this study, overexpression of Slug 
and Snail decreased both claudin-1 protein and mRNA levels.  In addition, Snail and Slug 
suppressed a claudin-1 promoter-reporter that contains wild-type E-boxes but not mutated E-
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boxes.  Direct in vitro binding of Snail and Slug to the E-box motifs in the human claudin-1 
promoter were further demonstrated by gel shift assays.  These data raise the possibility that 
deregulation of claudin-1 in cancer may be regulated by Snail and Slug.  
 
Beta-catenin/Tcf regulation of claudin-1 transcription 
  Beta-catenin is a transcriptional coactivator downstream of Wnt signaling that regulates 
gene expression through interaction with the transcription factor Tcf (T cell factor).  Constitutive 
activation of β-catenin/Tcf has been implicated in colorectal cancer [129, 130] due to activating 
mutations in the β-catenin gene or functional loss of adenomatous polyposis coli (APC).  APC is 
one of the components that facilitate β-catenin degradation.  Therefore functional loss of APC 
may lead to activated β-catenin/Tcf signaling [129].  It has been shown that ectopic expression of 
wild-type APC in APC-deficient colon cancer cells reduced both β-catenin and claudin-1 protein 
levels [124].  Claudin-1 was recently identified as a probable target of β-catenin/Tcf [124].  
Promoter study showed that two putative Tcf4 binding elements in the 5' flanking region of the 
human claudin-1 promoter are required for claudin-1 promoter activation induced by β-
catenin/Tcf [124], further supporting a role for β-catenin/Tcf in the transcriptional regulation of 
claudin-1.  As β-catenin/Tcf is frequently activated in colon cancer [130] and claudin-1 
contributes to metastatic transformation of colorectal cancer cells [125], active Wnt pathway 
may be involved in stimulation of claudin-1, thereby facilitating metastatic growth of CRC.  
 
Hypothesis 
 Cancer cells respond to a variety of steroid and polypeptide hormones and growth factors 
derived from non-tumor cells in tumor microenvironment [61].  Additionally, cancer cells can 
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synthesize and secrete growth factors that stimulate tumor progression through autocrine 
mechanisms [40].  Although the mechanisms underlying paracrine TGF-β regulation of tumor 
behavior is well documented, autocrine TGF-β regulation of tumor cell behavior is less well 
understood.  TGF-β has been shown to regulate the invasiveness and metastasis of carcinomas by 
stimulating the production of ECM-degrading enzymes [38].  The human metastatic breast 
cancer cells, MDA-MB-231, have active autocrine TGF-β signaling [63] and express both MMP-
9 and urokinase plasminogen activator (uPA) [51].  These findings raised the hypothesis that 
tumor cell-produced TGF-β regulates tumor behavior through regulation of MMP-9 or uPA 
activity in an autocrine manner.  Results from my studies show that the invasiveness of MDA-
MB-231 cells is correlated with autocrine TGF-β signaling.  Inhibition of autocrine TGF-β 
signaling attenuated basal uPA secretion but had no effect on basal MMP-9 production or 
activity.  Furthermore, inhibition of autocrine TGF-β signaling decreased uPA production And 
autocrine TGF-β regulation of uPA required Smad4 protein expression. With these findings, we 
conclude that tumor cells can be self-sufficient in promoting their own invasive growth by 
producing TGF-β, which in turn maintains basal uPA production that is critical for the invasive 
growth of these cells.   
 Smad4 was initially regarded as a tumor suppressor due to its role in mediating TGF-β-
induced antiproliferative responses [87, 88].  Recent evidence suggests additional tumor 
suppressing functions of Smad4 [85, 87, 88].  Loss of Smad4 activity is observed in about one 
third of colorectal cancer (CRC) metastases [84] and claudin-1 is an integral tight junction 
protein frequently over-expressed in CRC carcinomas and metastases [125].  Claudin-1 also has 
been shown to contribute to the metastatic transformation of CRC cells [125], raising the 
hypothesis that Smad4 acts as a tumor suppressor by inhibiting claudin-1 expression in CRC.  In 
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the second part of my study, inverse Smad4 and claudin-1 expression was observed in several 
metastatic CRC tissues and cell lines.  Smad4 expression resulted in specific downregulation of 
claudin-1 protein in two Smad4-deficient, claudin-1-positive colorectal carcinoma cell lines 
HT29 and SW480.  Promoter studies also show suppressed transcription of claudin-1 by Smad4 
expression.   
Previous findings by others suggest that Smad4 expression in Smad4-deficient SW480 
colon carcinoma cells did not restore cell growth inhibitory response to TGF-β presumably due 
to low levels of type II TGF-β receptor [85].  These data suggest that Smad4 may elicit tumor 
suppressive responses independently of TGF-β signaling.  Results from my studies show that in 
SW480 cells, ectopic Smad4 protein expression was not sufficient to restore TGF-β-induced 
promoter activation of the p3TP-Lux, a luciferase reporter construct highly responsive to TGF-β 
[31].  Moreover, treatment with the selective TGF-β receptor kinase inhibitor, LY364947, failed 
to prevent the inhibition of claudin-1 in Smad4 expressing SW480 cells.  In HT29 cells, although 
Smad4 re-expression restored autocrine and paracrine TGF-β signaling in terms of promoter 
activation of the p3TP-Lux, LY364947 did not prevent the Smad4 effect on claudin-1.  We thus 
conclude that Smad4 inhibition of claudin-1 expression is independent of TGF-β signaling in 
colorectal cancer cells.   
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell cultures and reagents 
  MDA-MB-231, RIE, HCT15, HCT116, SW480, SW620, HT29 cells from American 
Type Culture Collection (Manassas, VA, USA) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) (MDA-MB-231) or RPMI-1640 medium supplemented with 10% fetal bovine 
serum, 100 units/ml penicillin, and 100 µg/ml streptomycin in the presence of 5% CO2 at 37 °C.  
TGF-β was purchased from R & D Systems (Minneapolis, MN, USA).  The pharmacological 
TGF-β type I and II receptor kinase inhibitor (LY364947) [74] was provided by Eli Lily 
(Indianapolis, IN, USA).  Stable SW480 clones were generated by transfection with a Smad4 
expression vector followed by selection in 1 mg/ml G418 media.   
 
Plasmid construction 
   To construct the luciferase reporter plasmid under the control of the claudin-1 promoter, 
the -1160 to +160 upstream area of the human claudin-1 gene was amplified by polymerase 
chain reaction (PCR) using human genomic DNA with a set of forward and reverse primers 
containing MluI and XhoI restriction enzyme sites, respectively.  The sequences of the primers 
are 5’-TCGACGCGTACTCGCACCACACACAAAAA-3’ (forward primer with MluI site 
underlined) and 5’-CCGCTCGAGGTGCAGAAGGCGGAGAGTT-3’ (reverse primer with 
XhoI site underlined).  PCR was carried out in a 50 µl mixture containing 2.5 U of Taq DNA 
polymerase, 2 mM MgCl2, 250 µM dNTP (each), 0.4 µM of primers (each), and 100 ng human 
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genomic DNA.  Following an initial denaturation step at 95°C for 5 minutes, the PCR mixture 
was subjected to 35 cycles of denaturation, annealing, and amplification at 94°C for 40 seconds, 
58°C for 30 seconds, and 72°C for 40 seconds, respectively, and a final extension at 72°C for 5 
minutes.  The PCR product was size-fractioned by 1% (w/v) agarose gel electrophoresis, stained 
with ethidium bromide, excised from the gel, phenol/chloroform purified, and dissolved in water.  
After MluI and XhoI enzyme digestion, the PCR product was purified with phenol/chloroform 
then cloned into the promoter-less luciferase vector, pGL3-Basic (Promega, Madison, WI, USA) 
and the sequence of the PCR product was confirmed by sequencing analyses.   
 
Protein lysate preparation and immunoblotting analysis 
  To harvest protein lysates, cells on plates were rinsed with cold phosphate-buffered saline 
(PBS) and lysed in RIPA buffer [50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 µg/ml aprotinin, 1 µg/ml leupeptin, 
1 µg/ml pepstatin, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium orthovanadate, 
and 1 mM sodium fluoride] for 20 minutes on ice.  Lysates were sonicated and then clarified by 
centrifugation at 15,000 x g for 15 minutes at 4°C.  Protein concentrations of lysates were 
determined by the Bradford Assay (BioRad Laboratory, Inc., Hercules, CA, USA).  Proteins 
were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to PVDF membranes.  Membranes were blocked with 5% milk in PBS-T [0.1% 
Tween 20 (v/v) in PBS] for 1 hour at RT and then probed with primary antibodies in 5% milk 
PBS-T overnight at 4°C.  After several washes with PBS-T, membranes were incubated with 
horseradish peroxidase-conjugated secondary antibodies in PBS-T for 1 hour at RT and washed 
again with PBS-T.  Immunoreactive bands were visualized by chemiluminescence reaction using 
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ECL reagents (Amersham Life Science, Arlington Heights, IL, USA) followed by exposure of 
the membranes to XAR5 films (Kodak, Rochester, NY, USA).  To detect secreted uPA, 
conditioned media were collected, centrifuged at 15,000 x g for 5 minutes to remove cell debris, 
and then immunoblotted under non-reducing conditions.  The volumes of conditioned media 
loaded on gels were normalized to the protein concentrations of cell lysates.  The fibronectin 
antibody was purchased from Transduction Laboratories, Inc. (San Diego, CA, USA).  The 
Smad2 and phospho-Smad2 antibodies were obtained from Upstate Biotechnology, Inc. (Lake 
Placid, NY, USA).  The uPA antibody was obtained from American Diagnostica, Inc. 
(Greenwich, CT, USA).  The PARP and Rho GDI antibodies were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA, USA). The actin and FLAG antibodies were purchased 
from Sigma-Aldrich, Inc. (St. Louis, MO, USA).  The claudin-1, -4, and -7 antibodies were 
obtained from Upstate Biotechnology, Inc. (Lake Placid, NY, USA).  The Smad4 antibody was 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). The actin antibody was purchased 
from Sigma-Aldrich, Inc. (St. Louis, MO, USA).  The E-cadherin and β-catenin antibodies were 
purchased from BD Biosciences (San Jose, CA, USA). 
 
Preparation of plasma membrane fractions 
  Cells were collected in buffer containing 0.15 M NaCl, 20 mM HEPES, 2 mM CaCl2, 
100 µg/ml leupeptin, 2.5 mg/ml pepstatin A, and 1 mM phenylmethylsulphonylfluoride (pH 8.0) 
and lysed by freeze/thaw (liquid N2/42°C) cycles.  Nuclei were isolated from the suspension of 
lysed cells by centrifugation at 7,000 x g for 20 minutes at 4°C, washed three times, and re-
suspended in RIPA buffer.  The nucleus-free supernatant was spun at 100,000 x g for 1 hr at 4°C 
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to separate cytoplasm and membrane.   Membrane pellets were subsequently washed 3 times 
with 3 ml of the cell resuspension buffer and dissolved in RIPA buffer.   
 
Transient transfection and luciferase reporter assay 
 On the day before transfection, cells were seeded on 12-well plates in triplicate and 
allowed to grow overnight to 50-70% confluence.  The following day, cells were co-transfected 
with a firefly luciferase reporter construct and a reference construct containing Renilla reniformis 
luciferase, phRL-TK, (Promega, Madison, WI, USA) using Lipofectamine Plus reagents 
(Invitrogen, Carlsbad, CA, USA).  Four hours after transfection, cells were returned to regular 
culture media for 48 hours then lysed.  Firefly and R. reniformis luciferase activities were 
measured using the Dual Luciferase Reporter Assay System kit (Promega, Madison, WI, USA) 
in an Optocomp II Luminometer (MGM Instruments, Inc., Hamden, CT, USA).  Firefly 
luciferase activity was normalized to R. reniformis luciferase activity and plotted as mean ± SD 
from three independent experiments.  The phuPA-Luc promoter-reporter containing the -2345 to 
+30 region of the human uPA promoter was kindly provided by Dr. Shuji, Kojima [131]. The 
p3TP-Lux reporter was a generous gift from Dr. Joan Massague [132].  
 
Matrigel invasion assay 
  A modified Boyden chamber assay was performed using Transwells (8 µm pore size, 6.5 
mm in diameter) from Costar (Cambridge, MA, USA) and Matrigel (BD Biosciences, Bedford, 
MA, USA).  Transwell inserts were coated with 80 µg of Matrigel each and left for 3 hours at 
37°C before use.  Cells were trypsinized, washed with PBS, re-suspended in 0.2% BSA serum-
free medium, seeded onto Transwell inserts (50,000 cells/insert), and grown in the presence of 
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10% FBS in the medium in the lower compartment.  After 16 hours, cells remaining inside the 
inserts were removed with Q-tips and the cells that had traversed to the reverse side of the inserts 
were rinsed with PBS, fixed in 4% formaldehyde for 30 minutes at RT, and stained with 1% 
crystal violet for 1 hour to overnight at RT.  Cells were counted under a light microscope (at 400 
x power) and the number of invasive cell shown as the average of five areas on each insert.  Each 
invasion assay was performed in triplicate and repeated three times.   
 
Over-expression of Smad4 by Adenoviral infection 
  To amplify adenoviruses, the packaging 293T cells cultured in 5% serum DMEM at 80% 
confluence on P100 plates were infected with adenoviruses in 1 ml fresh 5% serum medium with 
rocking.  After 3 hours, 9 ml of 5% serum medium was added in each plate without removing 
infection medium.  Infected cells were allowed to grow for 3 days before being trypsinized and 
collected in 1 ml of 5% FBS medium, and subjected to three freeze/thaw cycles at -20°C/37°C.  
Adenovirus-containing supernatant was obtained from the cell suspension after centrifugation at 
15,000 x g for 20 minutes at 4°C and stored at -80°C.  The relative values of multiplicity of 
infection (MOI) of adenoviral suspension were determined by examining the cytopathic effect 
(CEP) in 293T.  Adenovirus with an MOI of 10-20 causes a total CPE in confluent 293T cells 3 
days post infection.  To perform adenoviral-mediated overexpression of Smad4, 70-80% 
confluent cells were washed once with PBS and infected with adenovirus at the indicated MOIs 
for three hours, then returned to regular serum media.  Cell lysates were harvested 48-72 hours 
post infection. 
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Cell proliferation (MTT) assay 
  Cells were seeded in 96-well plates (50,000/well) and the relative viable cell numbers 
were determined by MTT assay using the CellTiter 96 Non-radioactive Cell Proliferation Assay 
kit (Promega, Madison, WI, USA), following the manufacturer’s protocol.  MTT hydrolysis was 
determined by measuring the absorbance at 570 nm using a plate reader. 
 
MMP zymography 
  Serum-free conditioned medium was mixed with 2 x sample buffer (0.5 M Tris-HCl pH 
6.8, 5% SDS, 20% glycerol and 1% bromophenol blue) and subject to SDS-PAGE using 10% 
SDS-gelatin (1 mg/ml final concentration) gels under non-reducing conditions.  After 
electrophoresis, gels were soaked in washing buffer (50 mM Tris-HCl pH 7.5, 0.1 M NaCl, and 
2.5% Triton X-100) for 1 hour at RT to remove SDS and then in reaction buffer (50 mM Tris 
HCl pH 7.5 and 5 mM CaCl2 pH 8.0) overnight at 37°C.  Subsequently, gels were stained in 
staining buffer (0.15% Coomassie blue R250 in 10% acetic acid and 30% methanol) and de-
stained in the same staining solution without Coomassie blue R250.  Clear bands of pro- and 
active MMP-9 (92 kDa and 84 kDa, respectively) were observed against the blue background of 
stained gels. 
 
RNA isolation and Northern blot analysis 
  Total RNA isolated with the Trizol reagent was resolved on formaldehyde agarose gels, 
transferred, and immobilized onto Hybond-N nylon membranes (Amersham Life Science, 
Arlington Heights, IL, USA).  Blots were blocked in ULTRAHyb buffer (Ambion, Austin, TX, 
USA) for 3 hours at 65°C and probed with 32P-labeled antisense riboprobes (5 x 105 cpm/ml) in 
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ULTRAHyb buffer overnight at 68°C.  After several washes with low stringency (2 x SSC/0.1% 
SDS) and high stringency (0.1 x SSC/0.1% SDS) buffers at 68°C, images were acquired by 
autoradiography using a phosphorImager.  To prepare riboprobes, plasmids containing cDNAs 
were linearized, purified, and then subject to in vitro transcription using the MAXIscript kit 
(Ambion, Austin, TX, USA) in the presence of 50 µCi of [α-32P] UTP (800 Ci/ mmol) for 1 hour 
at 37°C.  Unincorporated nucleotides were removed using NucAway spin columns (Ambion, 
Austin, TX, USA). 
 
Nuclear run-on assay 
  Cell were collected, washed twice with PBS, and then re-suspended in lysis buffer (10 
mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2, and 1 mM DTT).  NP-40 was added to a final 
concentration of 0.2 to 0.5%, depending on the cell type.  After a 5-minute incubation on ice,  
nuclei were pelleted at 500 x g for 5 minutes, washed once with nuclear freezing buffer (50 mM 
Tris-HCl pH 8.3, 40% glycerol, 5 mM MgCl2, 1 mM DTT), and re-suspended in fresh nuclear 
freezing buffer.  In vitro run-on transcription was performed using 2 x 107 nuclei in 150 µl 
reaction buffer [5 mM Tris-HCl pH 8.0, 2.5 mM MgCl2, 150 mM KCl, 1 mM of ATP, CTP, 
GTP, 150 µCi of [α-32P] UTP (800 Ci/ mmol), 80 units of RNasin, and 2.5 mM DTT] during a 
30-minute incubation at 30°C.  Transcription was terminated by adding 350 µl of 
deoxyribonuclease I solution (20 mM Tris-HCl pH 7.4, 10 mM CaCl2, and 300 units of RNase-
free DNase I) and incubated for 30 minutes at 37°C.  Next, proteins were digested by adding 50 
µl of proteinase K solution (1% SDS, 5 mM EDTA, 1 mM Tris-HCl pH 7.4, and 300 µg/ml 
proteinase K) and incubated for 30 minutes at 50°C.  The 32P-labelled RNAs were 
phenol/chloroform purified and precipitated in 10% trichloroacetic acid plus 20 µg yeast tRNA.  
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After centrifugation at 15,000 x g for 1 hour, the RNAs were re-suspended in RNase-free H2O, 
denatured for 10 minutes at 65°C, and then chilled on ice.  The radiolabeled RNAs were 
hybridized to cDNAs pre-immobilized on membranes in hybridization buffer (50% formamide, 5 
x SSC, 5 mM EDTA, 5 x Denhardt’s solution, 0.1% SDS, and 100 ug/ml denatured salmon 
sperm DNA) for 48 hours at 42°C.  Next, the membranes were washed several times with 2 x 
SSC (1 x SSC = 0.15 M NaCl and 12.5 mM Na-citrate pH 7) and then with 2 x SSC plus 10 
µg/ml RNase A for another 30 minutes or not depending on intensity of background.  Signals 
were acquired and quantified with a PhosphorImager.  To immobilize cDNAs on nitrocellulose 
membranes, 1 µg linearized plasmid was denatured in 0.2 M NaOH for 30 minutes at RT and 
then neutralized with 10 volumes of 6 x SSC.  The DNAs were applied to nitrocellulose 
membranes using a slot blot apparatus and immobilized by UV crosslinking. 
 
RNA Interference 
  To perform Smad4 silencing, 70% confluent cells were transfected with 50 or 200 pM of 
a pool of four Smad 4 or scrambled siRNAs (Dharmacon, Lafayette, CO USA) using 
Oligofectamine (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s guideline.  
Conditioned media and protein lysates were harvested 3 days post transfection and subjected to 
immunoblotting. 
 
Immunofluorescence study 
  Cells grown in multi-chamber slides were fixed in 4% paraformaldehyde/PBS for 30 
minutes at RT and permeabilized in 0.1% Triton for 30 minutes at RT.  Cells were then blocked 
in 10% normal goat or donkey serum for 1 hour at RT followed by incubation with primary 
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antibody at the indicated dilutions (1:200 for claudin-1, Smad2, Smad1/5/8, and pSmad1/5/8 
antibodies; 1:400 for Smad4 and E-cadherin antibodies) in 2.5% normal goat or donkey serum 
overnight at 4°C.  After several washes with PBS, cells were incubated with FITC- or 
Rhodamine-conjugated secondary antibodies (Jackson Immunoresearch Laboratories Inc., West 
Grove, PA, USA) at a 1:400 dilution in 2.5% normal goat or donkey serum for 1 hour at RT.  
After PBS washes, cells were mounted with a DAPI-containing mounting medium and viewed 
under a fluorescence microscope.   
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CHAPTER III 
 
AUTOCRINE TGF-β REGULATES UROKINASE PLASMINOGE ACTIVATOR AND 
INVASIVENESS IN BREAST CANCER 
 
Abstract 
  Metastasis is a primary cause of mortality due to cancer.  Early metastatic growth 
involves both a remodeling of the extracellular matrix (ECM) surrounding tumors and invasion 
of tumors across the basement membrane.  Upregulation of ECM degrading proteases 
contributes to invasion of the basement membrane in tissues.  Autocrine TGF-β signaling may 
play an important role in cancer cell metastasis.  TGF-β regulation of tumor cell invasiveness has 
been linked with expression of uPA; however, little is known about the molecular mechanisms 
by which autocrine TGF-β regulates uPA or whether this regulation is causally linked with the 
invasiveness of tumor cells.  In the present study, inhibition of autocrine TGF-β signaling using a 
pharmacological inhibitor of TGF-β receptors (LY-364947) or with a dominant-negative TGF-β 
type II receptor decreased uPA secretion and tumor cell invasiveness.  Inhibition of uPA 
proteolytic activity with a blocking antibody decreased cell invasion to the same extent as did 
inhibition of autocrine TGF-β signaling.    Inhibition of autocrine TGF-β signaling decreased 
uPA protein secretion, but not intracellular uPA protein or mRNA levels.  In contrast, exogenous 
TGF-β increased uPA mRNA expression through RNA stabilization.  Blockade of TGF-β 
signaling with LY36497 efficiently inhibited Smad2 phosphorylation induced by TGF-β 
treatment, but did not affect the basal activation status of ERK, p38, Akt, and Src proteins, other 
potential effectors downstream of TGF-β signaling.  Further, suppression of Smad4 expression 
by RNA interference decreased uPA secretion.  We conclude that autocrine TGF-β regulates 
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uPA secretion via a Smad-dependent pathway, thereby promoting tumor cell invasion, whereas 
exposure to higher concentrations of exogenous TGF-β results in increased uPA mRNA stability 
leading to both increased production and release of uPA and further increases in cell 
invasiveness. 
 
Introduction 
  Malignant tumors are characterized by their ability to metastasize to distant organs.  The 
initial steps of metastasis involve invasive growth of tumors across the basement membrane and 
migration through the extracellular matrix (ECM).  As the enzymatic degradation of the 
basement membrane and ECM barriers requires a number of ECM-degrading proteases [38, 133] 
and is a critical early event in metastasis, invasiveness may be modulated by the expression of 
ECM-degrading proteases in tumor cells in response to autonomous and microenvironmental 
signals.  Among the increasing number of ECM-degrading proteases implicated in metastasis, 
considerable attention has been focused on the family of matrix metalloproteinases (MMPs) and 
the plasminogen activator system.  One of the regulators of these ECM-degrading proteases is 
transforming growth factor-β (TGF-β).   
  TGF-β is a multifunctional cytokine that regulates cell proliferation, differentiation, 
plasticity, and migration in a context-dependent manner (reviewed in references [68, 134]).  
TGF-β transduces signaling through a transmembrane type II receptor (TβRII), a constitutively 
active serine/threonine kinase receptor [135].  Upon ligand binding, the TβRII recruits and 
transphosphorylates intracellular TGF-β type I receptor (TβRI), thereby stimulating TβRI 
serine/threonine kinase activity [136].  The TβRI then activates the downstream effectors, Smad2 
and Smad3 by phosphorylation.  The activated Smad proteins form complexes with the common 
Smad mediator, Smad4 and then translocate to the nucleus, where the Smad complexes regulate 
 40
transcription of numerous TGF-β target genes.  Other signaling pathways may be activated by 
TGF-β depending on cell context.  These pathways include the extracellular signal-regulated 
kinases (ERK1/2) [17, 137], mitogen-activated protein kinase (p38) [138, 139], Src [111], and 
the phosphatidylinositol 3-kinase (PI3K) [62] pathways.  The precise molecular mechanisms of 
regulation of these pathways for TGF-β signaling and the physiological and pathological roles of 
TGF-β in normal tissues and cancer have not been completely defined. 
  Important roles for autocrine TGF-β in tumor progression and metastatic behavior have 
been supported by previous observations.  For instance, disruption of autocrine TGF-β signaling 
by a dominant-negative type II receptor (DNIIR) inhibited the invasive and metastatic potential 
of mammary and colon carcinoma cells [49].  This was attributed to prevention of autocrine 
TGF-β-induced epithelial-to-mesenchymal transition (EMT), a process believed to promote 
tumor cell migration and invasion [62].  Inhibition of autocrine TGF-β signaling by over-
expression of a soluble TGF-β type III receptor antagonized TGF-β activity and resulted in 
inhibition of tumor cell proliferation and induction of apoptosis [40].   
  The urokinase plasminogen activator (uPA) is a serine protease capable of initiating 
cascades of activation of ECM-degrading enzymes [64] and eliciting intracellular signaling 
through receptor binding.  Numerous studies have linked uPA to malignant phenotype of tumors 
[140, 141]; its role in invasion and metastasis has also been demonstrated in cell culture and 
animal models [51, 142].  Clinically, elevated uPA expression in tumors is associated with tumor 
aggressiveness and poor outcome in patients [65, 66].  The metastatic MDA-MB-231 breast 
cancer cells secrete active TGF-β [143, 144] and are TGF-β responsive [145].  These cells also 
express both the matrix metalloproteinases-9 (MMP-9) and uPA [51, 146, 147].  We 
hypothesized that autocrine TGF-β may function as a tumor promoter by regulating MMP-9 or 
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uPA activity in MDA-MB-231 cells.  The present study provides evidence that autocrine TGF-β 
regulates both cell invasiveness and uPA secretion. Inhibition of uPA activity is sufficient to 
suppress tumor cell invasion to the same extent as inhibition of autocrine TGF-β signaling, 
suggesting that autocrine TGF-β stimulation of invasiveness occurs via its regulation of uPA 
release.  The Smad pathway is required to regulate uPA levels as silencing of Smad4 results in 
inhibition of uPA secretion.  Interestingly, while autocrine TGF-β regulates uPA production 
through protein secretion, exogenous TGF-β further increases uPA expression, in part, through 
RNA stabilization.  Finally, this work demonstrates that a pharmacological kinase inhibitor of 
TGF-β receptors inhibits both uPA secretion and tumor cell invasiveness, thereby providing 
evidence for the potential efficacy of targeting TGF-β signaling for therapeutic intervention in 
cancer, and suggests that uPA expression or secretion may be an important mediator of such 
effects. 
 
Results 
 
Autocrine TGF-β signaling contributes to MDA-MB-231 cell invasion 
  The metastatic MDA-MB-231 breast cancer cells secrete active TGF-β [143, 144] and are 
TGF-β responsive [145].  The importance of autocrine TGF-β signaling in regulation of MDA-
MB-231 cell invasiveness was assessed by Matrigel invasion assays following abrogation of 
autocrine TGF-β signaling using the LY364947 compound [74], a kinase inhibitor of both TGF-
β type I and II receptor (TβRI and TβRII) by functioning as a potent ATP competitive inhibitor.  
  The inhibitory effect of LY364947 on TGF-β signaling was first validated by examining 
Smad2 phosphorylation.  Basal levels of Smad2 phosphorylation were undetectable by 
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Figure 7. The TGF-β receptor kinase inhibitor (LY364947) inhibited TGF-β
signaling and MDA-MB-231 cell invasion. (A) LY364947 inhibition of Smad2 
phosphorylation induced by TGF-β.  Cells were treated with vehicle, LY364947, 
TGF-β or in combination as indicated.   Forty five minutes later, cell lysates were 
collected and subjected to immunoblotting for total and phospho-Smad2. (B) 
LY364947 inhibition of basal and TGF-β-induced fibronectin expression.  Cells 
were treated with vehicle, LY364947, TGF-β, or in combination as indicated.  
Twenty four hours later, lysates were collected and subjected to immunoblotting for 
fibronectin and β-actin.  (C) LY364947 inhibition of basal and TGF-β-induced 
promoter activation.  Cells were transfected with the p3TP-Lux luciferase reporter 
construct as described in the “Materials and Methods” and then treated with 
vehicle, LY364947, TGF-β, or in combination as indicated.  Luciferase activity was 
determined 48 hours after treatments. (D) LY364947 inhibition of MDA-MB-231 cell 
invasion.  Cells were treated with LY364947 at the indicated concentrations 
overnight and then plated in Matrigel-coated Transwells in the presence of vehicle 
or increasing concentrations of LY364947 as indicated.  Sixteen hours later, cells 
on the reverse side of each Transwell membrane were stained and counted.  The 
data in (C) and (D) are expressed as fold changes relative to controls.  Results 
represent the average from three independent experiments ± SD.  * P < 0.05 and ** 
P < 0.003 are derived from one-way ANOVA with a Bonferroni correction. 
A.
5 ng/ml TGF-β - - +        +     
2.5 µM LY364947      - +        - +      
- Fibronectin
- β-actin
B.
D.
In
va
si
ve
 C
el
l N
um
be
r (
fo
ld
)
Matrigel Invasion Assay
- p-Smad2
- Smad2
5 ng/ml TGF-β - - +        +    
2.5 µM LY364947     - +        - +      
0
0.2
0.4
0.6
0.8
1
1.2
1.4
*
LY364947       0        0.1        1        10    µM
0
1
2
3
4
5
6
7
8
9
10
C.
5 ng/ml TGF- - - +          +  
2.5 M LY364947     - +         - +  
p3TP-Lux Reporter Assay
*
**
Lu
ci
fe
ra
se
 A
ct
iv
ity
 (f
ol
d)
 43
immunoblotting.  However, LY364947 abolished Smad2 phosphorylation induced by exogenous 
TGF-β without altering total Smad2 protein levels (Fig. 7A). Expression of fibronectin is 
induced by TGF-β through a Smad-independent pathway [148].  LY364947 also decreased both 
basal and exogenous TGF-β-induced fibronectin expression (Fig. 7B).  In addition, we evaluated 
the effect of LY364947 on TGF-β-induced promoter activation by reporter assays using p3TP-
Lux, a luciferase reporter construct highly responsive to TGF-β [132] and observed that 
LY364947 significantly inhibited both basal and exogenous TGF-β-induced promoter activation 
(Fig. 7C).  To investigate whether autocrine TGF-β has a role in regulation of MDA-MB-231 
invasiveness, Matrigel invasion assays were performed in the presence or absence of LY364947 
treatment.  LY364947 inhibited cell invasion in a dose-dependent manner (Fig. 7D). These data 
suggest that autocrine TGF-β plays a role in basal rates of MDA-MB-231 cell invasiveness. 
 
Expression of a dominant-negative TGF-β type II receptor suppresses  
autocrine TGF-β signaling and cell invasion 
  To substantiate the results obtained using the kinase inhibitor of TGF-β receptors, we 
assessed invasiveness of MDA-MB231 cells following suppression of autocrine TGF-β signaling 
with a dominant-negative TGF-β type II receptor (TβRII).  TβRII is the receptor responsible for 
ligand binding and for activation of TGF-β type I receptor through its kinase activity.  TβRII 
devoid of the kinase domain (DNIIR) acts as a dominant-negative mutant by competing with 
wild-type receptors for TGF-β ligands [149].  Expression of FLAG-tagged dominant-negative 
DNIIR was achieved using an adenoviral vector and was confirmed by immunoblotting for 
FLAG (Fig. 8A).  DNIIR expression was increased with increasing amounts of adenovirus 
whereas no DNIIR was detected in parental or the β-galactosidase adenovirus-infected cells.  
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Figure 8. Inhibition of TGF-β signaling by expression of a dominant-
negative TGF-β type II receptor (DNIIR). (A)  Over-expression of DNIIR-FLAG.  
Cells were infected with β-galactosidase (Ad-β-Gal) or DNIIR (Ad-DNIIR) 
adenoviruses at the indicated MOIs for three hours and allowed to grow in fresh 
media.  Forty eight hours later, lysates were prepared and subjected to 
immunoblotting for FLAG. (B) DNIIR inhibited Smad2 phosphorylation and 
fibronectin expression induced by TGF-β.  Forty eight hours after adenoviral 
infection, cells were treated with TGF-β for 45 minutes for phospho-Smad2 
immunoblotting or for 24 hours for fibronectin immunoblotting.  (C) DNIIR 
attenuated basal and TGF-β-induced promoter activation of p3TP-Lux.  Cells were 
infected with adenoviruses at an MOI of 30.  Twenty four hours after adenoviral 
infection, cells were transiently co-transfected with p3TP-Lux and phRL-TK and 
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were then lysed and the lysates were subjected to reporter assays.  *, P < 0.05 
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Expression of DNIIR inhibited TGF-β-stimulated Smad2 activation (Fig. 8B) and decreased both 
basal and exogenous TGF-β-induced fibronectin expression (Fig. 8B).  Expression of DNIIR 
also suppressed basal and exogenous TGF-β-stimulated p3TP-Lux promoter activation (Fig. 8C), 
demonstrating the inhibitory effects of DNIIR on TGF-β signaling.  As expected, DNIIR 
expression significantly decreased MDA-MB-231 cell invasion (Fig. 9A). This effect did not 
result from inhibition of cell proliferation as determined by MTT assay (Fig. 9B).  Thus, 
consistent with the results using the pharmacological inhibitor, inhibition of autocrine TGF-β 
signaling by the dominant-negative TGF-β type II receptor (DNIIR) downregulated MDA-MB-
231 invasiveness.  
      
Disruption of autocrine TGF-β signaling suppresses uPA secretion 
  The MDA-MB-231 cells secrete uPA [51].  To address whether autocrine TGF-β can 
modulate uPA expression, uPA levels were determined after blockade of autocrine TGF-β 
signaling using LY364947.  Immunoblotting for uPA was conducted under non-reducing 
conditions, which detect both uPA and complexes of uPA and its inhibitor, plasminogen 
activator inhibitor-1 (PAI-1) [150].  The low motility bands with molecular masses around 100 
kDa represent uPA/PAI-1 complexes (uPA ~55 kDa and PAI-1 ~52 kDa).  Our results show that 
LY364947 decreased uPA secretion in a dose-dependent manner (Fig. 10A) and that the 
decreased level of free uPA in the conditioned medium did not result from increased uPA/PAI-1 
association and depletion of uPA.  MDA-MB-231 cells constitutively express uPA receptor 
(uPAR) mRNA and exhibit detectable membrane-associated uPA [51].  To determine whether 
the decreased level of released uPA after LY364947 treatment was the result of increased uPAR 
expression and increased uPA binding to uPAR, levels of membrane-bound uPA were 
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Figure 9. Expression of the dominant-negative TGF-β type II 
receptor (DNIIR) decreased MDA-MB-231 cell invasion. (A) Cells 
were infected with adenoviruses at an MOI of 30.  Forty eight hours after 
adenoviral infection, cells were plated in Matrigel-coated Transwells (A) 
or 96-well plates (B) in triplicate.  After 16 hours, invasion (A) or MTT (B) 
assays were performed as described in “Materials and Methods”. *, P < 
0.05 is derived from one-way ANOVA with a Bonferroni correction; bars, 
standard deviation.
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Figure 10. The TGF-β receptor kinase inhibitor, LY364947, decreased
uPA but not MMP-9 protein levels in MDA-MB-231 conditioned media.  
(A) LY364947 decreased uPA secretion.  Cells were treated with LY364947 
at the indicated concentrations for 24 hours.  Conditioned media, cell 
lysates, and total RNAs were collected and subjected to immunoblotting for 
uPA and β-actin or Northern blotting for uPA and cyclophilin. (B) The effect 
of LY364947 on membrane association of uPA proteins.  Cells were treated 
with 5 µM LY364947 or 5 ng/ml TGF-β for 24 hours.  Membrane, 
cytoplasmic, and nuclear fractions were isolated as described in the 
“Materials and Methods” and subjected to immunoblotting for uPA, PARP 
(nuclear marker), Rho GDI (cytoplasmic marker), and β-actin.  (C) The 
effect of LY364947 on MMP-9 protein levels and activity.  Cells were 
treated with LY364947 at the indicated concentrations for 24 hours.  
Condition media were collected and subjected to gelatin zymography.
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determined after LY364947 treatment.  The purity of the membrane fractions was confirmed by 
the absence of nuclear and cytoplasmic proteins, PARP (polyadenosine diphosphate ribose 
polymerase) and Rho GDI, respectively (Fig. 10B).  Our results show that neither exogenous 
TGF-β treatment nor LY364947 treatment altered membrane uPA levels (Fig.  10B).  Inhibition 
of autocrine TGF-β signaling by expression of DNIIR also suppressed uPA secretion in a dose-
dependent fashion (Fig. 11).  In contrast, β-galactosidase adenovirus infection did not alter uPA 
secretion, further supporting that inhibition of autocrine TGF-β signaling suppresses uPA 
secretion.  Of note, expression of DNIIR was not detectable at an MOI of 10 by immunoblotting 
(Fig. 8A); however this low level of DNIIR expression was sufficient to decrease uPA secretion 
(Fig. 11).  These data demonstrate that disruption of autocrine TGF-β signaling inhibited uPA 
secretion.  
  Steady-state levels of uPA mRNA did not change with either LY364947 treatment or 
DNIIR expression (Fig. 10A and 11).  Further, while uPA release into the medium was decreased, 
the intracellular uPA were increased after blockade of autocrine TGF-β signaling (Fig. 10A and 
11), suggesting that autocrine TGF-β stimulates uPA secretion and that inhibition of autocrine 
TGF-β signaling reduces the level of secretion without impairing uPA production, thus leading 
to intracellular accumulation of uPA. 
  
Disruption of autocrine TGF-β signaling does not affect MMP-9 protein levels and activity 
  MDA-MB-231 cells express the MMP-9 protein [51] that is particularly important among 
at least 19 MMP proteins identified to date in tumor invasion and metastasis due to its ability to 
degrade the basement membrane component, type IV collagen.  We determined the effect of 
LY364947 on MMP-9 protein levels and activity.  Gelatin zymography shows no change in 
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Figure 11. Expression of the dominant-
negative TGF-β type II receptor (DNIIR) 
decreased uPA secretion. Cells were infected 
with β-galactosidase (Ad-β-Gal) or DNIIR (Ad-
DNIIR) adenoviruses at the indicated MOIs.  
Forty eight hours after infection, cells were 
cultured in fresh medium and allowed to grow 
for 16 hours. Conditioned media, protein 
lysates, and total RNA were harvested and 
subjected to immunoblotting for uPA and β-actin
or Northern blotting for uPA and cyclophilin. 
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either MMP-9 (92 kDa) protein levels or MMP-9 activity after LY364947 treatment (Fig. 10C), 
indicating that autocrine TGF-β does not regulate MMP-9 activity or protein expression in the 
MDA-MB-231 cells.  Consistent with previous reports [51], we did not detected MMP-2 (72 kDa) 
expression in MDA-MB-231 cells.    
      
Inhibition of uPA activity impairs MDA-MB-231 cell invasion 
  Inhibition of autocrine TGF-β signaling resulted in decreased invasiveness and uPA 
secretion as described above.  We next investigated a relationship between uPA activity and 
MDA-MB-231 cell invasiveness.  Inhibition of uPA activity using an anti-catalytic uPA blocking 
antibody attenuated cell invasion by ~70% as compared with no treatment or IgG treatment in 
Matrigel invasion assays (Fig. 12A), indicating a correlation between of uPA activity and MDA-
MB-231 cell invasiveness.  Parallel MTT assays suggest that the decreased cell invasion was not 
due to alterations in cell proliferation (Fig. 12B).  Thus, uPA activity contributes to cell 
invasiveness and uPA appears to be the important mediator of invasiveness due to autocrine 
TGF-β signaling.     
 
Smad4 RNA interference decreases uPA secretion 
  TGF-β receptors transduce signals through both the Smad pathway and the Smad-
independent pathways such as the extracellular signal-regulated kinases (ERK1/2) [17, 137], the 
p38 mitogen-activated protein kinase [138, 139], the phosphatidylinositol 3-kinase (PI3K) [62], 
and the Src [111] pathways.  Whether autocrine TGF-β regulates those Smad-independent 
pathways was evaluated by immunoblotting.  LY364947 treatment (up to 10 µM) did not 
significant alter activation status of ERK1/2, p38, Akt, and Src proteins (Fig. 13A).  In contrast, 
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Figure 12. Inhibition of uPA activity decreased MDA-MB-231 cell 
invasion. Cells were plated and grown in Matrigel-coated 
Transwells (A) or 96-well plates (B) in the presence or absence of 50 
µg/ml of a normal IgG or an uPA activity blocking antibody.  Sixteen 
hours later, invasive and viable cell numbers were determined by
Matrigel invasion and MTT assays, respectively, as described in the 
“Materials and Methods”.  * P < 0.03 is derived from one-way 
ANOVA with a Bonferroni correction; bars, standard deviation. 
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Figure 13. Smad4 silencing decreased uPA secretion. (A). 
Inhibition of autocrine TGF-β signaling by LY364947 did not alter 
activation status of ERK1/2, Akt, p38, and Src proteins.  Cells were 
treated with 0, 1, and 10 µM LY364947 for 24 hours and then lysed.  
Immunoblotting was performed using antibodies against total and 
active forms of ERK1/2, Akt, p38, and Src proteins. (B) Smad4 
silencing decreased Smad4 protein expression and uPA secretion. 
Cells were transiently transfected with a Smad4 or a scrambled 
control siRNA at the indicated concentrations for 24 hours.  Cells 
were then allowed to grow in fresh medium for another 24 hours. 
Conditioned media and lysates were harvested and subjected to 
immunoblotting for uPA, Smad2, Smad4, and β-actin. 
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as little as 0.1 µM of LY364947 suppressed uPA secretion (Fig. 10A), implicating that these 
pathways are probably not involved in autocrine TGF-β regulation of uPA secretion.   We 
hypothesized that the Smad pathway mediates the autocrine TGF-β effect on uPA secretion. In 
this case, downregulation of the common Smad mediator, Smad4, should suppress uPA release 
that results from autocrine TGF-β signaling.  Smad4 silencing was achieved using a mixture of 
four Smad4 siRNAs.  Immunoblotting results confirmed decreased Smad4 expression in Smad4 
siRNA-transfected cells but not in parental or scrambled control siRNA-transfected cells (Fig. 
13B).  Smad2 protein expression was unaffected by the Smad4 siRNA transfection, further 
confirming specific silencing of Smad4 protein expression by the Smad4 siRNAs.  Interestingly, 
uPA secretion was also decreased by inhibition of Smad4 protein expression (Fig. 13B), 
indicating that the Smad pathway is required for the regulation of uPA secretion by autocrine 
TGF-β.  
 
Exogenous TGF-β increases uPA mRNA levels through RNA stabilization 
  Exogenous TGF-β was previously shown to stimulate uPA expression and increased  
MDA-MB-231 cell invasiveness [51].  We further examined uPA regulation by exogenous TGF-
β.   Unlike autocrine TGF-β, exogenous TGF-β increased both uPA mRNA and protein levels in 
a dose-dependent manner (Fig. 14A).  A time course study shows that uPA mRNA was induced 
by TGF-β in a time-dependent fashion to near maximal levels by 16 hours after treatment and the 
level was sustained for at least 48 hours (Fig. 14B).  Increased mRNA expression is due to either 
increased transcription or increased RNA stability.  The transcription of uPA in response to 
exogenous TGF-β was determined by a nuclear run-on assay.  Exogenous TGF-β failed to 
enhance uPA transcription (Fig. 15A and B) but strongly stimulated transcription of PAI-1, a 
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Figure 14. Exogenous TGF-β increased uPA mRNA levels and 
protein secretion in a dose- and time-dependent manner. Cells 
were treated with increasing concentrations (0.1 – 10 ng/ml) of TGF-
β for 24 hours (A) or 5 ng/ml TGF-β for various intervals (B) as 
indicated.  Conditioned media, lysates and total RNA were harvested 
and subjected to immunoblotting for uPA or Northern blotting for uPA 
and cyclophilin, respectively. 
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TGF-β target gene that  has been shown to be transcriptionally activated by TGF-β [151].  
Consistent with the nuclear run-on result, transient expression assays using a uPA-promoter-
reporter construct containing the nucleotide -2345 to +30 region of the human uPA promoter 
(phuPA-Luc) show very little changes in uPA promoter activity after TGF-β treatment (Fig. 7C).  
In contrast, uPA promoter activity was significantly induced by PMA, a known inducer of 
activation of the human uPA promoter  [152] (Fig. 15C).  Next, the stability of uPA mRNA in 
the presence and absence of exogenous TGF-β was determined by examining uPA mRNA levels 
at various time points after blocking transcription with the RNA polymerase II-specific inhibitor 
DRB (5, 6- dichloro-1-β-D-ribofuranosyl-benzimidazole).  Quantitation of the Northern blotting 
results shown in Fig. 16A indicates that by 8 hours after DRB treatment, uPA mRNA levels were 
decreased by 50% in untreated cells (Fig. 16B).  In contrast, uPA mRNA levels were only 
decreased by 25% in TGF-β-treated cells, suggesting that exogenous TGF-β enhances the 
stability of uPA mRNA.  Thus, exogenous TGF-β increased uPA mRNA levels through mRNA 
stabilization in MDA-MB-231 cells. 
   
Discussion 
  TGF-β is a potent inhibitor of epithelial cell growth through inhibition of proliferation 
and induction of apoptosis [35, 153] and is an important tumor suppressor [154].  The tumor 
suppressor role of TGF-β is evident in that mice heterozygous for deletion of the TGF-β gene 
with expression of 10% to 30% of TGF-β levels of wild type animals, developed an increased 
number of chemically-induced tumors than did wild-type littermates [154].  However, escape 
from the growth inhibitory effects of TGF-β occurs frequently in cancer through numerous 
mechanisms.  TGF-β also displays tumor promoting effects in late-staged tumors.  TGF-β has 
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Figure 15. Exogenous TGF-β did not stimulate uPA transcription.
(A) After cells were treated with 5ng/ml TGF-β for 0, 3, or 24 hours, 
nuclei were harvested and subjected to nuclear run-on assays as 
described in “Materials and Methods”.  Signals were visualized and 
quantified by a PhosphorImager and plotted as fold change (B).  (C) 
Exogenous TGF-β did not increase uPA promoter activity.  Cells were 
co-transfected with phuPA-Luc and phRL-TK for 24 hours and then 
treated with TGF-β or PMA for 48 hours before reporter assays. All 
data are presented as the mean ± SD.  *, P < 0.03 and **, P < 0.01 are 
derived from one-way ANOVA with a Bonferroni correction.
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Figure 16. Exogenous TGF-β stabilized uPA mRNA.
(A) TGF-β decreased uPA mRNA turnover.  Cells were 
treated with vehicle or 5 ng/ml TGF-β for 16 hours and 
then with 20 µg/ml of DRB in the presence or absence 
of TGF-β.  Total RNA was isolated at the indicated 
times after DRB treatment and subjected to Northern 
blotting for uPA and cyclophilin.  (B) Cyclophilin-
normalized uPA mRNA levels from (A) were plotted as 
percentages of the uPA level at the 0 hour time point. *, 
P < 0.05 is derived from t test; bars, standard deviation. 
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been shown to facilitate tumor progression by inducing EMT [48, 155], ECM degradation [51], 
and cyclooxygenase-2 expression [156] or by inhibiting anti-tumor immune responses [59].    
  Disruption of tumor autocrine TGF-β signaling has been found to delay tumor growth 
and inhibit metastases [157] [49].  However, the molecular mechanisms underlying the 
tumorigenic effects of autocrine TGF-β remain unclear.  The present study demonstrates that 
autocrine TGF-β regulates both cell invasiveness and uPA secretion.  Inhibition of uPA activity 
decreases tumor cell invasion to the same extent as does the inhibition of autocrine TGF-β 
signaling.  Interestingly, while autocrine TGF-β regulates uPA availability via effects on protein 
secretion, exogenous TGF-β further increases uPA availability by increasing uPA mRNA 
through RNA stabilization.  Our data suggest two distinct levels of regulation of uPA in response 
to different magnitudes of stimulation by TGF-β.  The amount of active TGF-β in MDA-MB-231 
cell conditioned media has been quantitated at ~0.25 ng/ml [63, 143, 144] while at least 10-fold 
higher concentrations that were required to increase uPA mRNA levels (see Figure 6A).      
  Stabilization of mRNA involves the binding of RNA proteins to certain cis-elements of 
mRNAs [158].  Adenylate-uridylate-rich elements (AREs) are important regulatory cis-elements 
present in the un-translated regions (UTRs) of short-lived mRNAs such as proto-oncogenes, 
cyclooxygenase-2 [159] and c-fos [160] mRNAs.  TGF-β and Ras have been shown to 
synergistically stabilize the COX-2 mRNA through an ARE in the proximal 3’-untranslated 
regions (3'-UTRs) [159].  Given that MDA-MB-231 cells possess an activating Ki-Ras mutation 
[161] and that AREs are present in the 3’-UTR of the uPA mRNA [162], it is possible that TGF-
β may cooperate with the active Ras to regulate the stability of uPA mRNA through a similar 
mechanism, but confirmation of this awaits further investigation.  
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  Cells release uPA as a single-chain zymogen.  The low level of intrinsic proteolytic 
activity of pro-uPA [163] can convert the plasminogen in tumor microenvironments or Matrigel 
[164] to plasmin, which in turn activates pro-uPA.  This pro-uPA activation by plasmin and 
activation of plasminogen by uPA in a cyclic fashion promotes degradation of the extracellular 
matrix (ECM) or the basement membrane and facilitates cell invasion.  In addition, plasmin can 
potentially activate matrix metalloproteinases (MMPs) [64, 165, 166] thereby promoting ECM 
degradation and tumor cell invasion [167].  However, we did not find evidence for upregulation 
of MMP-9 activity or expression by TGF-β in the MDA-MB-231 cells under the conditions 
studied. 
  TGF-β is released from cells mostly in a latent, inactive form via a constitutive secretion 
pathway [168].  Despite the predominance of latency of TGF-β in conditioned media in general, 
MDA-MB-231 cells express detectable active TGF-β [63].  It is interesting that uPA can 
proteolytically activate latent TGF-β [7].  Therefore, TGF-β regulation of uPA production may 
be a positive feedback loop for activation of latent TGF-β (Fig. 17) and this relationship can be a 
cycle in cancer progression since TGF-β is over-expressed in both malignant breast tumors and 
surrounding stroma [169, 170] and uPA expression is increased in human breast carcinomas and 
bone metastases [171].  It will be of interest to determine whether the basal level of uPA 
secretion contributes to the availability of active TGF-β and autocrine TGF-β signaling. 
  The plasminogen activator inhibitor (PAI-1) is a TGF-β target gene and a strong inhibitor 
of uPA.  The present study demonstrates that TGF-β increases levels of both uPA and PAI-1 in 
the MDA-MB-231 condition media.  Interestingly, despite the fact that PAI-1 inhibits uPA 
activity, concomitant elevation of u-PA and PAI-1 has been observed in breast cancer and is 
associated with poor outcome [172], suggesting that tumor progression may occur in the 
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Figure 17. Schematic representative showing: 1) autocrine and 
paracrine TGF-β modulation of uPA via protein secretion and RNA 
stabilization, respectively, leading to a more invasive phenotype, 2) a 
potential positive feedback loop of activation of TGF-β by uPA.  
Autocrine TGF-β facilitates uPA secretion, which may in turn activate 
latent TGF-β produced by either tumor or stromal cells, and 3) induction 
of uPA by autocrine and paracrine TGF-β may cause subsequent ERK 
activation, loss of apoptotic responses, and increase proliferation that 
have impact on malignant cellular transformation.
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presence of high levels of PAI-1.  TGF-β has been shown to stimulate attachment and invasion 
through up-regulation of PAI-1 [43] and these effects may contribute to cell invasion.  Our 
findings suggest that while PAI-1 is induced by TGF-β, this induction is not sufficient to prevent 
the invasion promoting effect of uPA. 
  TGF-β receptor activation results in phosphorylation of Smads2/3 which then form a 
complex with Smad4, translocate to the nucleus and regulate transcription of target genes [1].  
While endogenous levels of Smad2 phosphorylation were below the limit of detection of 
immunoblot analysis, we found that silencing of Smad4 expression by siRNA was sufficient to 
inhibit release of uPA into the conditioned medium. Taken together, our results suggest that the 
basal regulation of uPA secretion in MDA-MB-231 cells is dependent on autocrine TGF-β 
receptor activation and Smad signal transduction. 
  In summary, autocrine TGF-β regulates both cell invasiveness and uPA secretion. 
Inhibition of uPA activity decreases tumor cell invasion by the same extent as inhibiting of 
autocrine TGF-β signaling, suggesting that autocrine TGF-β regulation of uPA levels associates 
with the invasiveness.  The Smad pathway is necessary to mediate regulation of uPA secretion 
by autocrine TGF-β.  Interestingly, while autocrine TGF-β regulate uPA production through 
protein secretion, exogenous TGF-β further increases uPA expression through RNA stabilization.  
Moreover, our study suggests that the efficacy of an inhibitor of TGF-β receptor activation can 
suppress tumor cell invasiveness and proves the uses for further study of small inhibitors as 
experimental caner therapeutic agents.  
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CHAPTER IV  
 
SMAD4 SUPPRESSES CLAUDIN-1 EXPRESSION THROUGH A TGF-β-  
INDEPENDENT PATHWAY IN COLORECTAL CANCER CELLS 
 
Abstract 
Smad4 is a central intracellular signal transduction component of the TGF-β family of 
cytokines and is considered an important tumor suppressor with the capacity to mediate TGF-β-
induced growth inhibition and apoptosis.  Clinically, loss of Smad4 protein expression is 
correlated with poor prognosis and is frequently observed in invasive and metastatic carcinomas 
of colorectal cancer (CRC).  The integral tight junction protein, claudin-1, has been recently 
observed to be increased in CRC carcinomas and metastases.  Moreover, claudin-1 levels are 
positively correlated with the metastatic potential of CRC cell lines.  In the present study, we 
report an inverse correlation between Smad4 and claudin-1 expression in several CRC 
carcinomas and cell lines.  Smad4 expression in Smad4 deficient, claudin-1-positive HT29 and 
SW480 cells, resulted in inhibition of claudin-1 protein expression.  Expression of other claudins 
such as claudin-4 and -7 was not altered by expression of Smad4, suggesting the specific 
regulation of claudin-1 by Smad4.  Smad4 expression in SW480 cells inhibited claudin-1 mRNA 
expression to undetectable levels as determined by RT-PCR and Northern blotting.  Moreover, 
Smad4 expression decreased claudin-1 promoter activity in reporter assays, suggesting 
transcriptional repression as a mechanism of claudin-1 inhibition by Smad4 expression.  The 
selective TGF-β receptor kinase inhibitor, LY364947, did not prevent the Smad4 suppression of 
claudin-1 protein expression in either SW480 or HT29 cells suggesting that the Smad4 effect on 
claudin-1 was independent of TGF-β signaling.  Thus, these findings suggest a novel mechanism 
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underlying Smad4 tumor suppressive function through regulation of a potential metastatic 
modulator, claudin-1, in a TGF-β independent manner in CRC cells.  
 
Introduction 
Smad4 is the central intracellular effector in mediating Smad-dependent signals from the 
TGF-β family of proteins that are composed of TGF-βs, activins, and bone morphogenetic 
proteins (BMPs) [173].  This family of proteins regulates a broad range of cellular responses 
including proliferation, differentiation, migration, and apoptosis during embryonic development 
and the maintenance of tissue homeostasis in the adult [15].  TGF-β family of proteins initiates 
signaling by binding and activating membrane serine-threonine kinase receptors.  Subsequently, 
the receptors activate two groups of receptor-associated Smad effectors (Smad2 and 3 for TGF-
βs and activins and Smad1, 5, and 8 for BMPs) by phosphorylation.  Activated Smads form 
oligomers with the common Smad effector, Smad4, and then translocate from cytoplasm to the 
nucleus to regulate gene expression independently or in association with other DNA-binding 
partners [5].  Smad4 thus has a central role in transducing Smad-dependent signaling from all 
members of the TGF-β family.   
Pathological TGF-β signaling has been implicated in various human diseases such as 
auto-immune diseases, vascular disorders, and cancer (reviewed in [22]).  In tumor-related 
biology, TGF-β has been focuses of studies as it is a prototype of growth inhibitor and apoptosis 
inducer in normal epithelial lineages and therefore is considered a cytokine with tumor 
suppressive activity.  Acquisition of resistance to the anti-proliferative effect of TGF-β allows 
tumor cells to escape from normal growth constraints, which may occur via mechanisms 
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involving loss or functional inactivation of the components (e.g. loss of the expression of Smad4 
or the TGF-β type II receptor) of the TGF-β signal pathway.   
Smad4, also termed DPC4 (deleted in pancreatic carcinoma, locus 4), was originally 
isolated from human chromosome 18q21.1 and is functionally inactivated in approximately half 
of pancreatic cancers [82], one third of metastatic colorectal carcinomas [84], and smaller 
subsets of other types of cancer.  Concomitant loss of Smad4 expression and acquisition of 
invasive and metastatic phenotype [86] strongly implicate tumor suppressive functions of Smad4 
in tumors.  Although Smad4 was initially regarded as a tumor suppressor through mediating 
TGF-β-induced antiproliferative responses [87, 88], recent evidence has suggested additional 
tumor suppressive functions of Smad4.  For instance, Smad4 expression in Smad4-deficient 
SW480 colon carcinoma cells resulted in loss of tumorigenicity of these cells in nude mice [87], 
re-establishment of a more epithelioid phenotype, and increased expression of E-cadherin and P-
cadherin [85].  Interestingly, Smad4 restoration did not alter growth inhibitory response to TGF-
β, which was attributed to low levels of type II TGF-β receptor resulting in deficient TGF-β 
signaling [85].  These data suggest that Smad4 may elicit distinct tumor suppressive responses 
independently of TGF-β signaling.  
Disruption of the cell-cell junctions with concomitant changes in the expression of 
junctional proteins is a critical event in invasive and metastatic progression in cancer.  While 
adherens junction proteins have been studied extensively in cancer, the roles of tight junction (TJ) 
proteins are less well characterized.  Claudins are recently identified members of the tetraspanin 
family of proteins that are integral to the structure and function of TJs.  Altered expression of 
claudins has been detected in several types of cancers; however, their roles in cancer remain 
unclear and controversial.  We have recently reported elevated claudin-1 expression in colon 
 65
carcinomas and metastases and observed a positive correlation between claudin-1 protein levels 
and tumorigenic and metastatic capacity in colorectal cancer (CRC) cell lines [125].  Therefore, 
claudin-1 appears to be an important regulator of metastatic transformation of tumor cells.  
Given that Smad4 is frequently lost while claudin-1 is over-expressed in metastatic 
colorectal cancer (CRC) [83, 84, 125], we have investigated their relationship in CRC.  In this 
present study, we report an inverse correlation between Smad4 and claudin-1 expression in CRC 
carcinomas and cell lines.  Furthermore, Smad4 expression in two Smad4-deficient but claudin-
1-positive CRC cell lines, HT29 and SW480, suppressed claudin-1 protein expression but did not 
change expression of other claudins such as claudins-4 and -7.  Expression of Smad4 appears to 
suppress claudin-1 transcriptional activity and markedly suppresses claudin-1 mRNA expression. 
In SW480 cells, the Smad4 effect on claudin-1 was independent of TGF-β signaling as ectopic 
Smad4 protein expression was not sufficient to restore TGF-β responsiveness as demonstrated in 
promoter study using the p3TP-Lux, a luciferase reporter construct that is highly responsive to 
TGF-β [31], in response to TGF-β.  Furthermore, treatment with the TGF-β receptor kinase 
inhibitor, LY364947, failed to prevent the inhibition of claudin-1 by Smad4 expression in 
SW480 cells.  In HT29 cells, although Smad4 expression restored an autocrine and paracrine 
TGF-β signaling in terms of promoter activation of the p3TP-Lux in HT29 cells, LY364947 did 
not prevent the Smad4-mediated suppression of claudin-1 expression, further supporting that 
Smad4 inhibition of claudin-1 expression occurs independently of TGF-β signaling.   
 
Results 
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Inverse Claudin-1 and Smad4 expression in colorectal carcinomas and cell lines 
Since loss of Smad4 protein expression is associated with advanced disease and is 
frequently detected in metastatic colorectal cancer (CRC) [84] and claudin-1 has been recently 
defined as a potential metastatic promoter in CRC cells [125], we examine the correlation 
between Smad4 and claudin-1 expression in CRC.  Expression of claudin-1 and Smad4 was 
examined in six pairs of normal and tumor tissues.  In normal tissues, Smad4 expression was 
invariably detected but claudin-1 expression is not detected by immunoblotting (Fig 18A).  
Inverse expression of Smad4 and claudin-1 was observed in five out of the six tumor tissues 
evaluated (Fig. 18A).  In a survey of several colorectal cancer and intestinal epithelial cell lines, 
claudin-1 protein expression was abundantly detected in the Smad4-deficient SW480, SW620, 
and HT29 lines, but it was not detectable in Smad4-expressing RIE, HCT 116, and HCT 15 lines 
(Fig. 18B).  Absence of claudin-1 protein expression is correlated with undetectable expression 
of claudin-1 mRNA as determined by semi-quantitative RT-PCR (Fig. 18B).  These data suggest 
an inverse expression of Smad4 and claudin-1 in colorectal carcinomas and cell lines. 
 
Smad4 reconstitution decreases claudin-1 protein and RNA expression 
To determine whether Smad4 can regulate claudin-1 expression, we examined claudin-1 
protein levels after Smad4 expression in the Smad4-deficient claudin-1-positive HT29 colon 
carcinoma cells.  Smad4 expression in HT29 cells was achieved by Smad4 adenoviral infection 
and confirmed by immunoblotting for Smad4.  Immunoblotting results show Smad4 expression 
only in Smad4-adenovirus (Ad-Smad4)-infected but not in parental or β-galactosidase-
adenovirus (Ad-β-Gal)-infected HT29 cells (Fig. 19A).  Smad4 expression resulted in decreased 
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Figure 18. Inverse Smad4 and claudin-1 protein expression in 
selected colorectal carcinomas and cell lines. (A) Tissue samples 
were obtained from six patients with colon cancer and designated as 
“N” for normal mucosa, “T” for primary tumor or “M” for liver 
metastases.  Protein lysates were prepared from homogenized 
tissues and clarified by centrifugation.  Equal amounts of lysates were 
used in immunoblotting assays for claudin-1, Smad4, and β-actin.  (B) 
Lysates and total RNA from the indicated cell lines were prepared as 
described in “Materials and Methods” and subjected to 
immunoblotting (IB) and semi-quantitative RT-PCR (RT-PCR) for 
claudin-1, Smad4, and β-actin. 
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Figure 19. Smad4 expression in Smad4-deficient colon cancer cell 
lines inhibited claudin-1 protein expression. (A) HT29 cells were 
infected with β-galactosidase (Ad-β-Gal) or Smad4 (Ad-Smad4) 
adenoviruses at the indicated MOIs.  Seventy two hours later, cells were 
lysed and the lysates were subjected to immunoblotting assays for the 
indicated proteins.  (B) Protein lysates and total RNA from SW480 
parental, vector, and three Smad4-expressing clones were obtained and 
subjected to immunoblotting (IB) for the indicated proteins, semi-
quantitative RT-PCR (RT-PCR) for claudin-1 and β-actin expression, and 
Northern blotting (NB) for claudin-1 and cyclophilin expression. 
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claudin-1 expression in a dose-dependent manner, indicating a causal role for Smad4 in the 
inverse relationship between claudin-1 and Smad4. 
      To further substantiate these findings and dissect the molecular mechanisms underlying 
Smad4-mediated inhibition of claudin-1, Smad4-expressing stable clones were derived from the 
SW480 cells (another Smad4-deficient but claudin-1-positive CRC line).   Three clones with 
stable Smad4 expression were selected and the claudin-1 levels in these clones were determined 
by immunoblotting.  Consistent with the observations in HT29 cells, Smad4 expression resulted 
in inhibition of claudin-1 expression.  This effect of Smad4 appears to be specific for claudin-1 
as levels of claudin-4 and -7 proteins did not change after Smad4 expression in both HT29 and 
SW480 cells (Fig. 17A and B).  Consistent with previous findings, Smad4 expression in SW480 
cells resulted in a mesenchymal-to-epithelial morphological change, increased E-cadherin, and 
down-regulation of β-catenin as determined by immunofluorescence and immunoblot studies 
(Fig. 20A and B).  These data show that Smad4 expression profoundly downregulated the 
expression of claudin-1 in colorectal cancer cells.  
 
Smad4 expression suppresses claudin-1 promoter activity  
The absence of detectable steady-state claudin-1 mRNA associated with loss of claudin 
protein expression (Fig. 19B) suggests suppressed transcription of claudin-1 by Smad4.  To 
study transcriptional regulation of claudin-1, a reporter assay-based promoter study was 
performed using a claudin-1 promoter-reporter construct containing the -1160 to +160 region of 
the human claudin-1 promoter or pGL3/-1.2Cld-1 (Fig. 21A).  In SW480 parental, vector alone, 
and three Smad4-expressing clones, luciferase activity of pGL3/-1.2Cld-1 was determined and 
normalized to that of pGL3-Basic, the backbone of pGL3/-1.2Cld-1.  A 34-48% reduction in 
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Figure 20. Smad4 re-expression resulted in a mesenchymal-to-epithelial 
morphological change, increased E-cadherin, and decreased β-catenin 
protein expression. (A)  Parental (a – d) and Smad4-expessing (e – h) 
SW480 cells grown on multi-chamber slides were photographed under a 
phase-contrast microscope and then subjected to E-cadherin and DAPI 
(nuclear) immunofluorescent staining. (B) Smad4 re-expression enhanced E-
cadherin but decreased β-catenin protein expression.  Whole cell lysates
were prepared from SW480 parental, vector, and three Smad4-expessing 
clones and subjected to immunoblotting for E-cadherin, β-catenin, and β-
actin.
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Figure 21. Claudin-1 promoter activity in parental, vector, and Smad4-
expressing SW480 clones. (A) Schematic of the claudin-1 promoter-
reporter that contains the -1160 to +160 region of the human claudin-1 
promoter (pGL3/-1.2Cld-1).  (B) SW480 parental, vector, and three Smad4-
expressing clones were transiently transfected with 0.2 µg of pGL3/-1.2Cld-
1 or pGL3-Basic (backbone of pGL3/-1.2Cld-1) along with 0.04 µg of a 
reference reporter (phRL-TK) in triplicate.  Forty eight hours after 
transfection, luciferase activity was determined and plotted as mean ± SD 
from three independent experiments.  Normalized luciferase activity 
(pGL3/-1.2Cld-1 versus pGL3-Basic) in each individual clone is presented 
as a percentage (100% in SW480 parental cells). SBE: Smad binding 
element. *, P < 0.05 is derived from one-way ANOVA with a Bonferroni
correction. 
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claudin-1 promoter activity was observed in Smad4-expressing clones when compared with that 
of SW480 parental cells (Fig. 21B).  In contrast, claudin-1 promoter activity was not 
significantly reduced in the control vector-stably transfected cells.  This inhibitory effect of 
Smad4 on claudin-1 promoter activity was also observed in transient co-transfection experiments 
in SW480 and SW620 cells, in which cotransfection of Smad4 decreased claudin-1 promoter 
activity (Fig 22A and B).  Thus, Smad4 appeared to suppress claudin-1 expression through 
transcriptional control and the necessary cis-elements are within the -1160 to +160 proximal area 
of the claudin-1 promoter.  
 
TGF-β signaling is not recovered by Smad4 expression and is not required for Smad4 
suppression of claudin-1 expression in SW480 cells 
 
SW480 cells secrete TGF-β [174].  To determine whether ectopic Smad4 expression 
restores TGF-β responsiveness establishing autocrine and paracrine TGF-β signaling and to 
determine whether TGF-β signaling is necessary for the effect of Smad4 expression on claudin-1 
expression in the SW480 cells, we sought evidence for TGF-β signaling.  This was done by 
examining nuclear accumulation of Smad4 and Smad2.  Intact TGF-β signaling results in 
translocation of the Smad2/3 and Smad4 complex to the nucleus in response to receptor 
activation.  Immunofluorescence confirms the expression of Smad4 in the selected SW480 stable 
clones but not in the parental cells (Fig. 23B).  Immunofluorescence showed no significant 
nuclear-localization of Smad2 in either parental or Smad4-expressing SW480 clones (Fig. 23A). 
Interestingly, the Smad4 staining was predominantly in the nucleus despite the absence of Smad2 
nuclear localization (Fig. 23B).   
We next examined whether Smad4 restores TGF-β-mediated promoter activation of 
p3TP-Lux, a luciferase reporter construct that is highly responsive to TGF-β [31].  Our results 
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Figure 22. Smad4 expression decreased claudin-1
promoter activity. SW480 (A) and SW620 (B) cells were 
co-transfected with 0.05 µg of a claudin-1 promoter-
reporter (pGL3/-1.2Cld-1), 0.04 µg of a reference reporter 
(phRL-TK), and 0.15 µg of a control or a Smad4 expression 
vector.  Reporter assay was performed 72 hours after 
transfection. *, P < 0.05 is derived from t test; bars, 
standard deviation. 
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Figure 23. Immunofluorescent staining for Smad2 (A) 
and Smad4 (B) in parental (a-c and d-f) and Smad4-
expessing (g-i and j-l) SW480 cells.  Parental and 
Smad4-expessing SW480 cells grown on multi-chamber 
slides were subjected to immunofluorescent staining for 
Smad4, Smad2, and DAPI (nuclear) and photographed 
under an up-right fluorescent microscope.   
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showed no induction of p3TP-Lux activity by TGF-β treatment in SW480 parental, vector, or 
Smad4 expressing clones (Fig. 24).  SW480 cells are known to express very low levels of the 
TGF-β type II receptor (TβRII) [85], which may explain why expression of Smad4 did not 
restore TGF-β responsiveness.  This hypothesis was further supported by transient co-
transfection experiments showing that TGF-β responsiveness was restored when TβRII was co-
expressed in Smad4-expressing SW480 (Fig. 24).  Thus, expression of Smad4 alone neither 
restored responsiveness to exogenous TGF-β nor established an autocrine TGF-β loop in SW480 
cells.  Therefore, TGF-β signaling may not be required for the Smad4 effect on claudin-1 
expression in these cells.  This conclusion was further supported by experiments using a TGF-β 
receptor kinase inhibitor, LY364947.  LY364947 is a potent ATP competitive inhibitor of the 
TGF-β type I and II receptors (TβRI and TβRII) and inhibits the kinase activity of the TGF-β 
receptors and TGF-β signaling [29].  Immunoblotting shows that LY364947 treatment did not 
prevent the inhibition of claudin-1 expression by Smad4 expression in the SW480 cells (Fig. 25). 
 
TGF-β response is enhanced by ectopic Smad4 expression and is not required for Smad4 
suppression of claudin-1 in HT29 cells 
 
HT29 is another cell line in which we observed the Smad4 inhibitory effect on claudin-1 
expression.  In contrast to SW480 cells, HT29 cells express sufficient levels of TGF-β type II 
receptor (TβRII) to transduce TGF-β-mediated Smad2 phosphorylation [175].   Nevertheless, 
TGF-β signaling to the nucleus is defective due to the deficiency of Smad4 expression (Fig. 18B, 
19A, and 26A).  In transient co-transfection experiments using, we found that TGF-β activated 
p3TP-Lux promoter in Smad4 co-transfected cells (Fig. 26A).   Of note, Smad4 co-transfection 
enhanced basal p3TP-Lux promoter activity, suggesting the establishment of 
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Figure 24. The TGF-β signaling pathway was not restored by Smad4 
expression but was restored by co-expression of Smad4 and wild-
type TGF-β type II receptor (RII) in SW480 cells. SW480 parental, 
vector, and Smad4 clones were transiently co-transfected with 0.05 µg
p3TP-Lux, 0.04 phRL-TK, and 0.15 µg of a control vector or a RII 
expression vector.  Sixteen hours after transfection, cells were treated with 
3 ng/ml TGF- β and allowed to grow for 48 hours before luciferase assays.  
Luciferase activity was plotted as mean ± SD from three independent 
experiments and represented as fold change (TGF-β treatment versus 
vehicle treatment) in each individual line. *, P < 0.05 is derived from t test 
(treatment vs. no treatment); bars.
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Figure 25. The TGF-β receptor kinase inhibitor, 
LY364947, did not affect Smad4-mediated 
suppression of claudin-1 expression in SW480 
cells. SW480 parental, vector, and three Smad4-
expressing clones were grown in the presence of 
vehicle or 5 µM of LY364947 for 48 hours and then 
lysed.  Equal amounts of cell lysates were used for 
immunoblotting for Smad4, claudin-1, and β-actin. 
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autocrine TGF-β signaling by Smad4 expression.  Although LY364947 inhibited basal and TGF-
β-induced p3TP-Lux promoter activation in Smad4 co-transfected cells (Fig. 26A), it did not 
prevent Smad4-mediated suppression of claudin-1 expression in HT-29 cells (Fig. 26B), 
confirming that the effect of Smad4 on claudin-1 expression is independent of TGF-β signaling 
in CRC cells. 
 
Autocrine BMP signaling is increased by Smad4 restoration 
As described above, Smad4 alone did not restore TGF-β signaling in SW480 cells and the 
Smad4 effect on claudin-1 did not require TGF-β signaling in both SW480 and HT29 cells.  
Interestingly, Smad4 was detected primarily in the nucleus of Smad4-expressing SW480 clones 
(Fig. 23B).  It is possible that another Smad4-dependent TGF-β related signaling pathway, such 
as BMP signaling, may be uncovered by Smad4 expression.  Intracellular localization of BMP-
related Smads (Smad1, 5, and 8) and phospho-Smad1, 5, and 8 (activated forms) were examined.  
Immunofluorescence showed both cytoplasmic and nuclear BMP Smads in parental and Smad4 
clones, whereas phospho-Smad1, 5, and 8 are primarily localized in the nuclei of these cells (Fig. 
27A).  As SW480 parental cells express low but detectable Smad4 protein (Fig. 18B), we can not 
rule out the possibility of existence of an active BMP signaling in parental cells.  Interestingly, 
we detected a substantial increase in BMP-induced promoter activation in a transient co-
transfection experiment using a BMP-responsive reporter (BRE2-Luc) in SW480 parental cells 
(Fig. 27B).  Consistently, BMP signaling was also elevated in SW480 Smad4 stable cells as 
compared with vector controls (Fig. 27C).  The increase in BRE2-Luc activity in the absence of 
exogenous BMP suggests that autocrine BMP signaling is activated by expression of Smad4 in 
the SW480 cells.  These data indicate that Smad4 reconstitution enhanced autocrine BMP 
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Figure 26.  The TGF-β signaling pathway was restored by Smad4 
expression but was not required for Smad4-mediated suppression of 
claudin-1 expression in HT29 cells.  (A) The TGF-β receptor kinase inhibitor 
LY364947 inhibited Smad4-restored autocrine and paracrine TGF-β signaling 
pathways.  Cells were transiently co-transfected with 0.1 µg p3TP-Lux, 0.01 µg 
phRL-TK, and 0.4 µg of a control vector or a Smad4 expression vector. 
Sixteen hours later, cells were left untreated or treated with 5 µM LY364947, 3 
ng/ml TGF-β, or in combination for 48 hours.  Cells were then lysed and 
subjected to reporter assays.  (B) The TGF-β receptor kinase inhibitor, 
LY364947, did not abrogate Smad4 suppression of claudin-1 in HT29 cells. 
Cells were infected with β-galactosidase (Ad-β-Gal) or Smad4 (Ad-Smad4) 
adenoviruses at the indicated MOIs for 3 hours and then cultured in the 
presence or absence of 5 µM LY364947 for 72 hours.  Lysates were prepared 
and subjected to immunoblotting for Smad4, claudin-1 and β-actin.  *, P < 0.05 
is derived from one-way ANOVA with a Bonferroni correction; bars, standard 
deviation.  
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Figure 27.  Smad4 re-expression enhanced autocrine BMP signaling in 
SW480 cells.  (A) Intracellular localization of Smad1, 5, and 8 (BMP-
associated Smads) and phosphor-Smad1, 5, and 8 in parental and Smad4-
expressing SW480 cells by immunofluorescent staining. (B) Smad4 
expression enhanced the promoter activity of a BMP-responsive reporter 
(BRE2-Luc).  SW480 cells were co-transfected with BRE2-Luc and either a 
pCMV-Smad4 or a control vector along with a reference reporter construct. 
Luciferase activity was measured 48 hours after transfection.  (C) Elevated 
BMP signaling in stable Smad4-expressing SW480 cells.  Vector-containing 
or Smad4-expressing SW480 cells were transiently co-transfected with either 
BRE2-Luc or pGL3-Basic (backbone of BRE2-Luc) and phRL-TK.  Forty eight 
hours later, luciferase activity was measured and plotted as mean ± SD of 
three independent experiments.  Normalized luciferase activity (BRE2-Luc 
versus pGL3-Basic) is presented as a percentage (100% in vector control 
cells). *, P < 0.05, is derived from t test; bars, standard deviation.  
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signaling.  Whether BMP signaling is involved the Smad4 effect on claudin-1, E-cadherin, and 
reversal of EMT is currently under investigation.  
 
Discussion 
Smad4 is a key signal transduction mediator for the TGF-β family of cytokines.  Its 
cellular functions are commonly investigated as a central player of this signaling pathway and a 
tumor suppressor.  Loss of Smad4 function has been linked to advanced disease and worse 
prognosis in colorectal cancer [84, 86].  Smad4’s tumor suppressor functions have been linked to 
TGF-β-induced growth inhibition and apoptosis.  Interesting, Smad4 expression in Smad4-
deficient cells results in increased E-cadherin expression, reversal of EMT, reconstitution of 
intercellular adhesions, and loss of in vivo tumorigenicity of the cells [176, 177].  These findings 
provide evidence for additional tumor suppressive functions of Smad4. 
The tight junction protein claudin-1 is increased in CRC carcinomas and metastases and 
plays a role in the regulation of metastatic progression in CRC cells [125].  In the current study, 
we report that Smad4 is a negative regulator of claudin-1 possibly through transcriptional control 
in the colorectal carcinoma cells SW480 and HT29.  Of note, SW480 cells with low endogenous 
Smad4 protein expressed lower levels of claudin-1 than SW620 cells, which expressed 
undetectable Smad4 by immunoblotting.  These two lines were derived from the same patient 
with CRC (SW480 from primary carcinoma and SW620 from a liver metastasis) [178] and 
showed differential metastatic potential in nude mice,  positively correlating with claudin-1 
levels in our recent study [125].  Therefore, data obtained from these two lines further support 
the observation that there is an inverse relationship between Smad4 and claudin-1.  The 
downregulation of claudin-1 by Smad4 may be one of the mechanisms by which Smad4 
functions as a tumor suppressor in gastrointestinal epithelium.   
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In studying the requirement of TGF-β signaling for the Smad4 effect, we observed that 
Smad4 expression was not sufficient to establish an autocrine TGF-β loop nor did it restore 
responses to exogenous TGF-β unless TGF-β type II receptor was co-expressed in SW480 cells.  
In contrast to SW480 cells, Smad4 reconstitution restored the TGF-β response in HT29 cells, 
suggesting that both TβRII and Smad4 are the limiting factors in SW480 cells while Smad4 
limits TGF-β responsiveness in HT29 cells.  In these two cell culture models, the profound effect 
of Smad4 on claudin-1 expression was not affected by blocking TGF-β signaling with the TGF-β 
receptor kinase inhibitor LY364947.   
Interestingly, in the absence of active TGF-β signaling in SW480 cells, Smad4 was 
predominantly localized to the nucleus, an indication of active Smad signaling.  As Smad4 is the 
common effector in transmitting Smad-dependent signaling from all members of the TGF-β 
family of cytokines, it is possible that another Smad4-dependent TGF-β-related signaling 
pathway that does not utilize Smad2 and 3 as effectors, namely bone morphogenetic protein 
(BMP) signaling, may be uncovered by Smad4 expression.  A functional assay of BMP signaling 
using a reporter construct containing BMP-responsive elements in the promoter area showed 
significant increases in basal BMP signaling upon Smad4 expression.  Interestingly, BMP-7 has 
been shown to reverse TGF-β-induced EMT in renal tubular epithelial cells and mammary ductal 
epithelial cells through a Smad-dependent pathway [179].  Therefore, it is possible that BMP 
signaling is involved in Smad4-mediated reversal of EMT and suppression of claudin-1 in our 
cell model systems.   
E-cadherin expression is particularly important in tumor suppression as it maintains 
epithelial integrity and restrains cells from movement through tight cell-cell contacts.  In addition, 
its expression results in recruiting and antagonizing the activity of β-catenin, a known proto-
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oncogene downstream of Wnt signaling as well as a positive regulator of claudin-1 [124].  Beta-
catenin regulates target gene expression by functioning as a co-activator of the transcription 
factor Tcf/Lef-1 (T cell factor/lymphoid enhancer-binding factor-1) [180].  Therefore, re-
appearance of E-cadherin upon Smad4 restoration [85] (Fig. 18A and B) may impair 
transcriptional activity of β-catenin/Tcf, leading to altered gene expression in SW480 cells.  
Indeed we have performed a functional assay to determine the transcriptional activity of β-
catenin/Tcf/Lef-1 by transient expression experiments using reporters that have either wild-type 
(TOP-Flash) or mutant β-catenin/Tcf (FOP-Flash) responsive elements in the promoters.  In 
SW480 parental, vector, and Smad4 stable clones, significantly decreased β-catenin/Tcf activity 
was only detected in the Smad4 clones (data not shown).  Given that claudin-1 is a target gene of 
β-catenin/Tcf and that the β-catenin/Tcf elements are present within the -1160 to +160 region of 
the claudin-1 promoter appeared to be sufficient to mediate Smad4-inhibited promoter activity, 
impaired Wnt signaling may contribute to the transcriptional inhibition of claudin-1.   
The claudin-1 promoter has a canonical Smad binding element (SBE) in the -1160 to 
+160 area (Fig. 3A) and is negatively regulated by Smad4 in SW480 cells.  Smads bind DNA 
with low affinity and specificity [15, 173] and therefore, they generally need to interact with 
other transcription factors or co-factors to achieve specific transcriptional regulation.  For 
instance, Smad4 is able to inhibit the promoter activity of selected genes in association with 
transcriptional co-repressors such as Nkx3.2 [181], TGIF, and the Ski family of proteins [81, 182] 
that are able to recruit other co-repressors or histone deacetylases.  It will be important to 
determine whether Smad4 regulation of claudin-1 transcription involves similar mechanisms. 
Taken together, our findings demonstrate a novel TGF-β independent mechanism for the 
tumor suppressive functions of Smad4 through the inhibition of claudin-1 expression.  
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CHAPTER V 
 
SIGNIFICANCE 
 
 In this dissertation, my work has extended our understanding of the roles of TGF-β and 
Smad4 in tumor promotion and suppression.  In “Autocrine transforming growth factor-β 
regulates urokinase plasminogen activator and invasiveness in breast cancer cells”, a molecular 
mechanism underlying the tumor promoting effect of autocrine TGF-β has been identified.  My 
studies demonstrate that tumor cells can be self-sufficient in maintaining a malignant phenotype 
by producing TGF-β, which then acts in an autocrine manner to promote a regulator of the 
activity of ECM-degrading enzymes, urokinase plasminogen activator (uPA) thereby 
maintaining tumor cell invasive growth.  Interestingly, autocrine TGF-β regulates uPA through 
protein secretion, whereas paracrine TGF-β stimulates uPA expression by stabilizing mRNA, 
suggesting distinct molecular mechanisms of regulation of gene (uPA) expression in response to 
different magnitudes of stimulation (TGF-β).  Furthermore, although Smad4 is predominately 
considered as a tumor suppressor, it mediates TGF-β-induced uPA production with a tumor 
promoting effect in breast cancer cells.  My work also demonstrates the efficacy of a TGF-β 
receptor kinase inhibitor in suppressing tumor cell invasiveness providing evidence for the 
potential of a small-molecule TGF-β signaling inhibitor for therapeutic intervention in cancer. 
Claudin-1 is an integral tight junction protein that we recently found to be increased in 
CRC carcinomas.  Elevated expression of claudin-1 is correlated with the metastatic potential of 
CRC cell lines.  In the “Smad4 suppresses Claudin-1 transcription in colorectal cancer in a TGF-
β-independent pathway” study, Smad4 expression in Smad4-deficient, claudin-1-positive HT29 
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and SW480 cells resulted in inhibited expression of claudin-1.  Furthermore, the Smad4 effect on 
claudin-1 expression was independent of TGF-β signaling.  Smad4 was initially regarded as a 
tumor suppressor through mediating TGF-β-induced antiproliferative responses.  My study 
suggests a novel mechanism underlying Smad4 tumor suppressive functions through regulation 
of a potential metastatic modulator, claudin-1 and this Smad4 effect does not require TGF-β 
signaling.   
In summary, my studies have provided further understanding of 1) the molecular 
mechanism by which tumor cells maintain malignant phenotype by producing cytokine to 
promote their own invasive capacity in an autocrine manner, 2) a role for Smad4 in mediating 
TGF-β pro-tumorigenic effect, and 3) a novel TGF-β signaling-independent mechanism 
underlying Smad4 tumor suppressive functions.  
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CHAPTER VI 
 
FUTURE DIRECTIONS  
 
Smad4 restoration in SW480 colon carcinoma cells resulted in loss of tumorigenicity in 
nude mice, reversal of EMT, re-expression of E-cadherin [85, 87], and downregulation of 
claudin-1.  The effect of Smad4 expression on claudin-1 in these cells is independent of TGF-β 
signaling.  Smad4 restoration elevated endogenous BMP signaling in these cells (Fig. 24).  BMP 
has been implicated in reversal of EMT [179].  It will be of interest to determine whether 
downregulation of claudin-1 mediates loss of tumorigenicity in nude mice, reversal of EMT, re-
expression of E-cadherin after Smad4 restoration in SW480 cells, the mechanisms of how 
claudin-1 is regulated by Smad4 transcriptionally, and whether BMP signaling is involved in 
Smad4 regulation of claudin-1. 
 
Determine whether Smad4 regulates EMT and tumorigenicity through suppression of 
 claudin-1 expression in SW480 cells 
Epithelial and mesenchymal markers (e.g. E-cadherin and vimentin, respectively) and in 
vivo tumor formation (tumor size and incidence) will be determined with or without forced 
expression of claudin-1 in Smad4-expressing stable SW480 clones.  Specifically, one of the 
Smad4-expressing SW480 stable clones (SW480:Smad4) with an inducible claudin-1 gene 
(SW480:Smad4:i-claudin-1) under the control of tetracycline or doxycycline (Tet-Off system) 
will be generated.  Claudin-1 protein expression in response to doxycycline will be determined 
by immunoblotting.  Expression of E-cadherin and vimentin proteins will be examined in 
SW480:Smad4:i-claudin-1 with (in the absence of doxycycline) or without (in the absence of 
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doxycycline) claudin-1 expression by immunoblotting.  If forced claudin-1 expression prevents 
reversal of EMT induced by Smad4 expression, tumorigenicity of SW480:Smad4:i-claudin-1 
with or without forced claudin-1 expression will be determined.  SW480:Smad4:i-claudin-1 cells 
will be subcutaneously injected into nude mice, which will be treated with or without 
doxycycline (2 mg/kg) in their drinking water.  Tumor growth will be assessed non-invasively at 
2-week intervals by contrast enhanced CT imaging.  Incidence of tumor formation and tumor 
size will be assessed at autopsy when the tumor mass approaches 20% of the body mass.  
Claudin-1 and Smad4 protein expression will be examined in tumors by immunoblotting. 
 
Determine the molecular mechanism for Smad4 suppression of claudin-1 transcription 
Rational: The claudin-1 promoter has a canonical Smad binding element (SBE) (Fig. 26) 
and is negatively regulated by over-expression of Smad4 in SW480 cells.  Smad4 is known to 
inhibit gene expression by suppressing promoter activity in association with transcriptional co-
repressors, such as Nkx3.2, TGIF, and Ski, that recruit still other co-repressors or histone 
deacetylases [81, 181].  
 
Define the region(s) in the claudin-1 promoter required for the suppression of  
claudin-1 transcription by Smad4 
 
    In the result sections, a ~1.3 kb region of the claudin-1 promoter was shown to be 
sufficient to mediate Smad4 suppression of claudin-1 promoter activity.  Promoter studies will be 
conducted using reporters directed by a series of 5’deletions of the 1.3 kb claudin-1 promoter 
(Fig. 26) to identify area(s) necessary for transcriptional regulation by Smad4.  Consecutive 5’ 
deletions will be generated by PCR using four forward primers and a single reverse primer and 
then cloned into pGL3-Basic vector.  Promoter activity of these reporters and pGL3-Basic/-
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1.3hCla-1 will be determined and compared with SW480:Smad4 cells.  We will also perform 
assays utilizing promoter-reporter constructs with mutation(s) in the identified region to confirm 
the specificity of the sequence required for the Smad4-dependent regulation of claudin-1 
transcription.   
 
                                                                                                            
 
 
 
 
 
 
 
 
Determine Smad4 interaction with the claudin-1 promoter 
To test whether Smad4 binds to the SBE in the claudin-1 promoter in vitro, gel shift 
assays will be conducted using nuclear extracts of SW480 parental, SW480:vector, and 
SW480:Smad4 clones and radiolabeled SBE oligonucleotides.  Specific protein and DNA 
interaction will be confirmed using a molar excess of either cold or hot mutant SBE 
oligonucleotide competitors.   The presence of Smad4 in the protein/DNA complexes will be 
determined by super shift assays using Smad4 antibody and IgG (as a negative control).   
After assessing in vitro Smad4 binding to the SBE, chromatin immunoprecipitation (ChIP) 
assays will be conducted to determine cellular in vivo binding of Smad4 to the claudin-1 
SBE Luciferase
pGL3-Basic/-1.3 hCla-1 (-1160~+160)
-1160                                                            +160
SBE
+1
Luciferase
SBE Luciferase
SBE Luciferase
SBE Luciferase
PCR primers
SBE Luciferase
 Fig. 28:  Schematic diagram showing promoter-reporter constructs 
containing 5’ serial deletions or mutations of the claudin-1 
promoter, location of canonical Smad binding elements (SBEs) in 
the human claudin-1 promoter, and primers for generation of a 
series of 5’ deletion of the 1.3 kb upstream region of the claudin-1 
promoter. 
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promoter.  Briefly, SW480 variants in media will be incubated with 1% formaldehyde in the 
media to cross link proteins and DNA in vivo.  Cells will then be lysed and subjected to 
sonication to obtain chromatin complexes containing ~500 bp genomic DNA fragments.  Pellets 
of the chromatin complexes will be collected from the lysates by centrifugation, dissolved in a 
ChIP assay buffer, and then subjected to Smad4 immunoprecipitation using a Smad4 antibody 
(no addition of antibody will be included in experiments as a negative control) and protein A/G 
beads.  The DNA-protein cross-links in the immune complexes eluted from beads will be 
separated by a 12 hour-incubation at 65°C and then subjected to protein and RNA digestion.   
Subsequently, DNA will be purified and subjected to PCR using primers flanking the SBE site of 
the human claudin-1 promoter.  Chromatin complexes before IP or IP with IgG will be included 
in experiments as positive and negative controls, respectively. 
 
Identify transcriptional co-repressors associated with Smad4 
Smads may negatively regulate promoter activity of certain genes in association with 
transcriptional co-suppressors [81, 181].  If Smad4 in vivo binds to the claudin-1 promoter, we 
will examine the association between Smad4 and known Smad-binding co-repressors. Smad4 
immunosdprecipitation using the nuclear extracts of SW480 variants followed with 
immunoblotting for Nkx, TGIF, Ski, and SnoN will be performed.  At the conclusion of the 
experiments, in vivo association of these factors and Smad4 on the SBE of the claudin-1 
promoter will be examined by ChIP assays using respective antibodies. 
 
Determine whether BMP signaling plays a role in EMT reversal in  
Smad4 expressing SW480 cells 
      Rationale:  Smad4 expression in SW480 cells resulted in down-regulation of claudin-1  
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independently of TGF-β signaling and an increase in BMP signaling.  BMP signaling has been  
implicated in reversal of EMTEMT [179]. 
We will determine whether blocking autocrine BMP signaling using recombinant Noggin 
protein [12] or BMP neutralizing antibody can 1) block BMP-driven transcription of a BMP 
reporter construct and 2) inhibit the downstream effects caused by Smad4 in SW480 cells, 
including reversal of EMT, suppression of claudin-1 and re-expression of E-cadherin.  
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